



# 41st Congress of the Société Internationale d'Urologie

Featuring the 6th SIU Global Nurses' Educational Symposium

10-14 November, 2021

## PARTNER ACTIVITY GUIDE



In conjunction with

10<sup>th</sup> Emirates International

**UROLOGICAL**  
Conference



**SIU**  
Around the  
**WORLD**  
**DUBAI** 2021


[www.siu-urology.org](http://www.siu-urology.org)

in f t #SIU2021

Destination Partner

**دبي**

**SYMP-22 • Saturday, November 13, 2021**  
1245-1415 Gulf Standard Time (UTC+4) • Room: Sheikh Maktoum BC



## IMMUNOTHERAPY IN MIUC

### CURRENT PRACTICES AND FUTURE PERSPECTIVES

#### CHAIR



James Catto  
MB, ChB, PhD, FRCS(Urol)  
United Kingdom

#### MODERATOR



Peter Black  
MD, FACS, FRCS  
Canada

#### PANELISTS



Syed Hussain  
MBBS, MSc, MD, FRCP  
United Kingdom



Srikala Sridhar  
MD, MSc, FRCP  
Canada



J. Alfred (Fred) Witjes  
MD  
The Netherlands

Watch this session and claim 1 ECMEC® credit.

This session will be transmitted live via the SIU Congress platform, SIU @U

This session is supported by SIU Corporate Sponsor Bristol Myers Squibb.



#SIU2021 #SIUatU



# TABLE OF CONTENTS

---



## 41st Congress of the Société Internationale d'Urologie

Featuring the 6th SIU Global Nurses'  
Educational Symposium

**10-14 November, 2021**

Message from the SIU President	04
Message from the Congress and Local Organizing Committee Chairs	05
COVID-19 Health and Safety Precautions	07
General Information	08
SIU 2020 and 2021 Award Winners	13
Programme-at-a-Glance	24
Industry Supported Sessions	32
SIU 2021 Exhibit Floorplan	40
Partner and Exhibitor Listing	42
Sponsor Acknowledgements	56

*All information is accurate at time of print.*

---



Sanjay Kulkarni  
President

## Welcome from THE PRESIDENT OF THE SIU

Welcome Friends!

As you hold this Partner Activity Guide in your hand, or flip the pages online, you are part of a long-awaited return to in-person congresses for the international urology community! While we have banded together over the past year and half to continue supporting the advancement of urological education and training online, seeing you all face-to-face is a true pleasure!

A feat like this is only possible with the incredible standing support of the SIU Board of Directors, committees and councils, expert faculty, dedicated attendees, and of course our valued Industry partners. Thanks to the support of our corporate sponsors, congress contributors, gold, silver and bronze sponsors, destination partner and exhibitors, SIU is once again able to host a dynamic and meaningful in-person event. We also appreciate the support of the Dubai Department of Tourism and Commerce Marketing for their collaboration as our Destination Partner.

Please take some time to review the many activities on offer in Dubai and make the most of this return to face-to-face meetings!

Sincerely,

Kulkarni S.B.

Sanjay Kulkarni  
India  
President



Rafael Sanchez-Salas  
Canada  
Congress Organizing Chair



Abdulqadir Alzarooni,  
United Arab Emirates  
Co-Chair



Yasser Farahat  
United Arab Emirates  
Co-Chair

## The Congress and Local Organizing Committee CHAIRS

Dear Friends, Colleagues and Partners,

SIU 2021, held in conjunction with the 10th Emirates International Urological Conference of the Emirates Urological Society (EUS), is a true testament to the importance and power of cross-border collaboration!

Over the past two years, the local and international organizing committees have come together with the common goal of providing a state-of-the-art educational activity for the global urology community. With a focus on the safety and well-being of all attendees, we have been able to plan a dynamic and innovative event that has adapted to the many twists and turns of the pandemic.

Thank you, especially, to Scientific Programme Co-Chairs, Drs Christopher Evans and Rajeev Kumar, their committee members, and faculty – local and international – who have dedicated many hours to this important educational activity.

Of course, we also extend our gratitude to our Industry Partners, whose many activities and areas of support can be found in this document. Be sure to review their company profiles and visit those who are exhibiting both in person and online via the *SIU@U* exhibit hall.

After spending 2020 and 2021 at a distance, we are excited to welcome you to Dubai!

Sincerely,

A handwritten signature in black ink, appearing to read 'Rafael Sanchez-Salas'.

Rafael Sanchez-Salas  
Canada  
Congress Organizing Chair

A handwritten signature in black ink, appearing to read 'Abdulqadir Alzarooni'.

Abdulqadir Alzarooni  
United Arab Emirates  
Co-Chair

A handwritten signature in black ink, appearing to read 'Yasser Farahat'.

Yasser Farahat  
United Arab Emirates  
Co-Chair

**SYMP-23 • Saturday, November 13, 2021**

1245-1400 Gulf Standard Time (UTC+4) • Room: Sheikh Maktoum A



## What Makes a Penile Implant Patient Happy?

Best Practices for Improving Patient and Partner Satisfaction after PPI in 2021

### Chair



Steven Wilson  
MD, FACS, FRCS  
United States

### Panelists



Sébastien Beley  
MD  
France



Rafael Carrion  
MD  
United States



David Ralph  
BSc, MS, FRCS (Urol)  
United Kingdom



Koenraad van Renterghem  
MD, PhD  
Belgium

**Watch this session and claim 1 ECMEC® credit.**

This session will be transmitted live via the SIU Congress platform, SIU @U

This session is supported by SIU Corporate Sponsor Coloplast.




#SIU2021 #SIUatU



# COVID-19 Health and Safety Precautions

It is important to:



Always be aware of and maintain social distancing (2m between people)



Wear a mask. Masks may only be removed for food and beverage consumption in designated areas only



Follow proper hygiene protocols, including frequent hand washing, sanitization and cough/sneeze etiquette



Dispose of masks, gloves and tissues in PPE bins



Bring your own notepads and pens



Use the same seat throughout the session



Follow directional signage and adhere to maximum capacities in all areas

# GENERAL INFORMATION



## Venue

### Dubai International Convention & Exhibition Centre (DICEC)

Dubai World Trade Centre, Trade Centre 2  
Sheikh Zayed Road  
Dubai, United Arab Emirates

## Abstract Book

SIU 2021 Abstracts have been published as a supplement to SIU's official journal, *SIUJ*. This supplement is available, open-access at [www.siu-j.org](http://www.siu-j.org). Participants can view the SIU 2021 Abstract book via links on *SIU@U* and the Congress Mobile App.

*The SIU 2021 Abstract Book is supported by SIU Corporate Sponsor*



## Badges

For security purposes, delegates and exhibitors must wear their name badges to all social events, scientific sessions and the exhibit hall. Badges are included in your registration package.

## Broadcasting



More than 40 hours of select programming will be broadcast via SIU's virtual congress platform, *SIU@U*, and remain available on-demand through February 14, 2022. In-person registrants have complimentary access to the platform: [www.siu-urology.org/siuatu](http://www.siu-urology.org/siuatu). If you cannot locate your log-in details, please write to [congress@siu-urology.org](mailto:congress@siu-urology.org).

As of February 14, 2022, recorded sessions will be available via SIU Academy for viewing by SIU Members and SIU Academy members. For more information on SIU Academy, visit [www.siu-urology.org](http://www.siu-urology.org).

*The SIU@U platform is supported by SIU Corporate Sponsor*



## Certificate of Attendance

Personalized certificates of attendance will be sent digitally following the Congress. A hard copy can be printed upon special request in the speaker preview room.

## Continuing Medical Education

The 41st Congress of Société Internationale d'Urologie, Dubai, United Arab Emirates, 10/11/2021–14/11/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 28 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

*Missed any sessions in Dubai? Catch some key sessions on-demand on SIU@U and claim CME credits until February 14, 2022.*

## Congress Housing

Please visit the SIU Housing Desk in the registration area for assistance with your accommodation needs. MCI United Arab Emirates is the official Housing provider for the 2021 SIU Congress. For queries by email, contact [SIU2021-Congress@mci-group.com](mailto:SIU2021-Congress@mci-group.com).

## Registration/Congress Services Schedule

Registration is located outside the Sheikh Rashid Hall on the main level and is open during the following hours. SIU has implemented a no-contact registration process to protect delegates and staff.

Wednesday, November 10	0700–1700
Thursday, November 11	0700–1600
Friday, November 12	0700–1700
Saturday, November 13	0700–1700
Sunday, November 14	0700–1600

## GENERAL INFORMATION

### Speaker Preview Room

The Speaker Preview Room is located in Ajman A. Presenters are asked to check in with staff at the Speaker Preview Lounge at least 24 hours before their scheduled presentation. All presentations should be uploaded in the Speaker Management System in advance to reduce the amount of in-person contact required.

Personalized certificates of presentation will be sent by email following the congress, upon request.

<b>Wednesday, November 10</b>	<b>0700–1700</b>
<b>Thursday, November 11</b>	<b>0700–1700</b>
<b>Friday, November 12</b>	<b>0700–1730</b>
<b>Saturday, November 13</b>	<b>0700–1730</b>
<b>Sunday, November 14</b>	<b>0700–1530</b>

### Exhibit and Sponsor Information

The Exhibit Hall is located Sheikh Rashid Hall E

Delegates are asked to respect the directional arrows when visiting the exhibit hall, as well as maintain social distancing and refer to signage at each booth indicated the permitted number of occupants at one time.

### Exhibit Hall Schedule

<b>Thursday, November 11</b>	<b>1200–1700</b>
Exhibit Opening and Networking Event	
<b>Friday, November 12</b>	<b>1000–1630</b>
Coffee Break	1045–1115
Networking Lunch	1245–1415
Coffee Break	1545–1615
<b>Saturday, November 13</b>	<b>1000–1630</b>
Coffee Break	1045–1115
Networking Lunch	1245–1415
Coffee Break	1545–1615

### Gamification

Delegates can participate in the SIU 2021 Scavenger Hunt, hosted through the Congress mobile app. By completing a series of tasks, participants will be entered for a draw to win from 1 of 3 exciting prizes. The scavenger hunt is open to both in-person and online participants. Make sure to [download the app](#) for more info!



### Moderated ePosters

These sessions are held in various rooms. All ePosters are available for viewing from screens in the ePoster viewing area in the Exhibit Hall.

## Visit SIU's uRCADE and earn 1 European CME Credit (ECMEC®)

[www.siu-urology.org/urcade/urcade](http://www.siu-urology.org/urcade/urcade)

These games are made possible by unrestricted educational grants from **F. Hoffmann-La Roche Ltd.**, and SIU Corporate Sponsor **Merck & Co., Inc.**

### uRCADE

#### RCC Quest


Renal Cell Carcinoma

**CLICK HERE**

#### I-O+ Challenger

Bladder Cancer

**CLICK HERE**

The I-O+ Challenger is endorsed by  **World Bladder Cancer Patient COALITION**

# GENERAL INFORMATION

## SIU 2021 Mobile App

The SIU Congress app is available for download via the App Store, Google Play and the Windows Phone Store, or by [clicking here](#).

The Congress App features:

1. Access to digital final programme and abstract book
2. List of Exhibitors and Sponsors
3. Session polling and evaluations
4. Digital scavenger hunt featuring great prizes
5. Interactive venue maps

## SIU Academy® Awards

The SIU Academy Governance Committee is pleased to announce the presentation of the SIU Academy Awards for Outstanding Content in 2020. The awards will be given at the start of [Plenary Session 02 on Saturday, November 13](#).

## SIU Membership

Become a part of the international urology community and benefit from high-quality educational resources and programmes, unique networking opportunities, an inclusive and accessible academic publication and more. Learn more about SIU Membership by visiting our membership desk in the registration area, or contacting us at [membership@siu-urology.org](mailto:membership@siu-urology.org)

## Social Media in f t

Follow us on LinkedIn, Facebook and Twitter! [#SIU2021](#) is the official hashtag of SIU 2021! Connect with virtual participants, share your congress highlights and take-home messages and be sure to tag us [@SIU\\_urology!](#)

Take a glance at what everyone is saying on any of the live display monitors available throughout the congress venue. Make sure to follow our list of SIU 2021 Social Media Moderators and get the top session highlights directly to your phone!

## The uTech Charging Lounge

The Lounge is located in the exhibit hall. Participants can catch up on emails while charging mobile devices, laptop computers and tablets. We ask participants not to leave any device unattended in this area. The SIU is not responsible for lost, stolen or damaged devices. Each station will undergo proper cleaning and sterilization after each use.

*The uTech Charging Lounge is supported by SIU Corporate Sponsor*



## Unmoderated ePosters and Videos

Unmoderated ePosters and Videos accepted for SIU 2021 can be viewed via the free [SIU Academy app](#), or in the designated poster-viewing area (Sheikh Rashid Hall E) in the DICEC, during Congress hours.



## Useful Coordinates

Ambulance	998
Dubai Health Authority	800-342
Police	999

Dubai International Airport  
[www.dubaiairports.ae/contact](http://www.dubaiairports.ae/contact)

SIU Information  
[congress@siu-urology.org](mailto:congress@siu-urology.org)



Complimentary WiFi is available throughout the DICEC. WiFi users can connect via the network below:

Network: @DWTC Free-WiFi

## Testing (PCR)

PCR testing will be available during SIU 2021. It will be located in the ground floor of the Parking across the street from the DWTC (five-minute walk).

**Operator:** AlTadawi Medical Centre

**Timing:** 0900-1800

**Results:** Stamped and sent via email (within 24 hours)

**Price:** AED 150 per test

**Payment:** Credit card (preferred) and cash payment (available as an option). Official receipt will be provided for any form of payment.

**Registration:** Visitors will be asked to scan the QR code to book a slot online and fill their information before taking the test. QR code will be available around the venue.



**Location:** Al Mustaqbal Street Parking

**Location Map:** <https://bit.ly/3jwyNET>

# 25<sup>th</sup> PANHELLENIC UROLOGICAL CONGRESS

OCTOBER  
6-9  
2022

Grand Hyatt Conference Center  
ATHENS-GREECE

*Greek Urology at its best!*

*A National Conference with a global perspective!*



YEARS 1931-2021

For more information visit [www.huonet.gr](http://www.huonet.gr)

## About CUA

Chinese Urology Association (CUA) was the first Urological association in new China founded in 1981 by the founder of Chinese Urology, academician Jieping Wu in very difficult conditions after the culture revolution when a thousand things wait to be done in China. Forty years since the establishment of CUA, members of CUA forged ahead with enterprising spirit, with this spirit passed from generation to generation. The members of CUA are both realistic and innovative, who exert their utmost effort and attracted worldwide attention and achieved great reputation. CUA is developing along all these years and now it has become modernized in academic, scientific in management and internationalized in its development, forging core strength in promoting the development of Urology in China. The 12<sup>th</sup> CUA committee, including 77 members was selected by voting in November, 2020.

## 12<sup>th</sup> CUA Executive Committee



**Jian Huang**  
President  
CUA Governance



**Xu Zhang**  
President-elect  
CUA Clinical researches



**Zhangqun Ye**  
Past-president



**Liping Xie**  
Vice president  
CUA International relations



**Qiang Wei**  
Vice president  
CUA Education and guidelines



**Lin Qi**  
Vice president  
CUA Science popularization  
and philanthropy



**Junhua Zheng**  
Vice president  
CUA Congress and publicity



**Tianxin Lin**  
Secretary general  
General Coordination



**Nianzeng Xing**  
Vice secretary general



**Kunjie Wang**  
Vice secretary general



**Xin Ma**  
Vice secretary general

## CUA Sub-specialty Groups

Young Urologists Committee

Andrology Group

Basic Science Group

Female Urology Group

Infection and Inflammation Group

Kidney Transplantation Group

Laser Group

Minimally Invasive Group

Chair: Jian Huang

Chair: Tie Chong

Chair: Yuanjie Niu

Chair: Tiejun Pan

Chair: Junhua Zheng

Chair: Ye Tian

Chair: Lin Qi

Chair: Liping Xie

Nursing Group

Pediatric Urology Group

Primary-level Medical Group

Urinary Continence Group

Urolithiasis Group

Urological Oncology Group

Urology & Andrology Engineering Group

Urology Robotics Group

Chair: Wei He & Xuexia Ma

Chair: Huixia Zhou

Chair: Qiang Wei

Chair: Limin Liao

Chair: Zhangqun Ye

Chair: Jian Huang

Chair: Ming Liu

Chair: Xu Zhang



Anthony Atala  
United States

## SIU-Mostafa M. Elhilali Award 2020

### Anthony Atala, MD

Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of the Department of Urology at Wake Forest University. His work focuses on growing human cells, tissues, and organs. Dr. Atala works with several journals and serves in various roles, including editor-in-chief of STEM CELLS Translational Medicine and Bioprinting, and section editor for the Journal of Urology's Urology Survey. Dr. Atala is also on the editorial board of 11 journals. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is the editor of 22 books, has published more than 800 journal articles, and has applied for or received over 250 national and international patents.

Dr. Atala was elected to the National Academy of Medicine, and is a recipient of the US Congress-funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society; the Edison Science/Medical Award; the R&D Innovator of the Year Award; and the Smithsonian Ingenuity Award. Dr. Atala's work was twice listed among Time Magazine's top 10 medical breakthroughs of the year, and was ranked by the Project Management Institute among the top 10 most impactful biotech projects from the past 50 years. Dr. Atala was named by Scientific American as one of the world's most influential people in biotechnology, by U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, by Life Sciences Intellectual Property Review as one of 50 key influencers in the life sciences intellectual property arena, and by Nature Biotechnology as one of the top 10 translational researchers in the world.



Mark Emberton  
United Kingdom

## SIU-Mostafa M. Elhilali Award 2021

**Mark Emberton**, MB BS, FRCS (Urology),  
MD, FMedSci

Mark Emberton is the dean of the Faculty of Medical Sciences at University College London (UCL), where he is also a professor of interventional oncology. He is an honorary consultant urologist at the UCL Hospitals (UCLH) National Health Service (NHS) Foundation Trust and a National Institute for Health Research (NIHR) Senior Investigator (awarded in April 2015).

He previously worked as the director of the UCL Division of Surgery and Interventional Science, the Cancer Pathway Lead Prostate Cancer UCL Partners, and the UCLH NHS Foundation Trust Clinical Director of Cancer Services.

Dr. Emberton has demonstrated an ability to achieve clinical innovation resulting in measurable clinical benefit on a number of occasions. In each of these large team efforts, the results have been embraced by international clinical practice guidelines and have changed practice. The areas of innovation include the management of benign prostatic hyperplasia (BPH) using a self-management program in order to reduce drug utilization; the development of prostate magnetic resonance imaging (MRI), which has transformed the prostate cancer diagnostic pathway; and, most recently, the development of minimally invasive treatments for men with prostate cancer that avoid the side effects associated with standard whole gland treatments.

Dr. Emberton's clinical activity focuses on prostate cancer (novel diagnostic methods, risk stratification methods, minimally invasive treatments, decision analysis/clinical innovation), oncology (tumour models), and clinical epidemiology (alternatives to the randomized clinical trial).

Dr. Emberton has won numerous awards, including the BMA Innovation Award (2015), the BMJ Paper of the Year (2018), and the William Farr Medal of the Royal Society of Apothecaries (2014). He is a Fellow of the Academy of Medical Sciences (2015) and has published over 500 scientific papers.

Earlier this year (2021) he was conferred the title of Officer of the Order British Empire (OBE) in Her Majesty the Queen's Birthday Honours for his services to prostate cancer research.



Badrinath Konety  
United States

## Felix Guyon Medal 2020

### **Badrinath Konety, MD, MBA**

Badrinath Konety is the Henry P. Russe Dean, Rush Medical College; the senior vice president of clinical affairs at the Rush System for Health, Rush University; and a professor of urology. He is the former chair of the department of urology, associate director for clinical affairs of the Masonic Cancer Center at the University of Minnesota, and vice dean for clinical affairs and CEO of the University of Minnesota Physicians.

Dr. Konety completed his residency and American Foundation for Urologic Disease Research Scholar Fellowship at the University of Pittsburgh. He also received his MBA from the University of Pittsburgh Katz School of Business and completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center.

He has authored or co-authored 300 peer-reviewed publications and numerous book chapters, as well as editing books on bladder cancer. He has been and is principal investigator or coinvestigator on grants funded through the US Department of Defense, National Institutes of Health, American Geriatrics Society, and Centers for Disease Control and Prevention. He has received the Jahnigen Career Development Scholar Award and the Ferdinand Valentine Fellowship.

Dr. Konety is an active member of numerous professional medical societies, including the American Urological Association, the American College of Surgeons, the Société Internationale d'Urologie (SIU), and the American Association of Genitourinary Surgeons. He is the past president of the SIU and the Society of Academic Urologists, and is an associate editor of the Journal of Urology. He has been recognized for several years by the Best Doctors of America and Top Doctors of America annual lists.



Peter Hammerer  
Germany

## Felix Guyon Medal 2021

### **Peter Hammerer**, MD, PhD

Since 2003, Prof. Dr. med. Peter Hammerer has led the Urology Clinic of the Academic Hospital in Braunschweig, which is one of the largest Hospitals in Germany. He is an internationally renowned expert in the field of the diagnosis and treatment of urological cancers. He is on the board of directors of the German Cancer Group (Association of Urological Oncology (AUO)), leading the prostate group, and was chairman of the congress organizing committee of the Société Internationale d'Urologie (SIU).

He was section editor of European Urology and co-editor of numerous scientific journals. He was a member of the board of directors of the European School of Urology (ESU) and is past president of the European Association of Urology (EAU) Section of Oncological Urology (ESOU). He is also past president of the Northern German Urology Association.

In 2019, Prof. Dr. med. Hammerer was elected as incoming chairman of the World Urologic Oncology Federation (WUOF). The purpose of the WUOF is to provide a formal liaison between the national urooncological working groups on a global level.

After studying medicine at the University of Hamburg, Germany, and at the University of Tucson, USA, Prof. Dr. med. Hammerer was trained at the University Hospital Hamburg and at the Free University Berlin as a specialist in urology. In 1991, he became assistant professor of urology at Stanford University, USA, working with Profs. Thomas Stamey, John McNeal, and others with a focus on prostate cancer. In 1993, he returned to Germany, where he worked until 2002 as vice-chairman at the University Hospital Hamburg-Eppendorf (UKE). In 1996, he completed an additional qualification as a doctor for special urological surgery. He also holds the additional title Medical Oncology and Genetics for the field of urology.

Prof. Dr. med. Hammerer is involved as principal investigator (PI) in many phase 1, phase 2, and phase 3 clinical trials in urooncology, biomarkers, and imaging. His main research topics include urological oncology; prostate cancer research, diagnosis, and therapy; nerve-sparing radical prostatectomy; and men's health.



Serigne Magueye Gueye  
Senegal

## SIU-Albert Schweitzer International Teaching Award 2020

### Serigne Magueye Gueye, MD, FWACS

Dr. Serigne Magueye Gueye is professor of urology at the University Cheikh Anta Diop, Dakar, Senegal, and chair of urology and andrology, Grand Yoff General Hospital General Idrissa Pouye, a Société Internationale d'Urologie (SIU)-accredited centre in Dakar, offering postgraduate training and building capacity to residents and consultants from Africa and the rest of the world.

An active clinician with expertise in various aspects of urology, he has a focus on urologic oncology, male sexual and reproductive health, and urogenital reconstructive surgery. Dr. Gueye has published more than 150 peer-reviewed articles.

He has been the principal investigator (PI) or co-PI on many research grants supported by the American National Cancer Institute (NCI)/National Institutes of Health (NIH). He is the editor-in-chief of the *Revue Africaine d'Urologie et d'Andrologie* (URO'ANDRO). Dr. Gueye is an international member of the American Urological Association (AUA), a member of the American Society of Clinical Oncology (ASCO), and a founding member of the MADCaP (Men of African Descent and Carcinoma of the Prostate) Consortium. He co-initiated the PAUSA Initiative for Urology Training in Africa, which is a collaborative project of a global philanthropic committee composed of the SIU, the AUA, the European Association of Urology (EAU), and IVUmed.

Dr. Gueye runs training workshops and teaches surgery and urology in many sub-Saharan African countries. His centre hosts trainees from all over Africa, as well as International Federation of Gynecology and Obstetrics (FIGO) scholars, to learn obstetric fistula surgery.

He has trained fistula surgeons in many African countries, such as Senegal, Mauritania, Benin, Chad, Gabon, The Gambia, Guinea Bissau, Democratic Republic of the Congo, Rwanda, Mozambique, Madagascar, and Eritrea, and in Asia (Pakistan and Indonesia).

For his work, Dr. Gueye has received national and international awards, including the United Nations Medal for Peace in Rwanda (1994); Croix de la valeur militaire française avec Etoile de Bronze (1994); Chevalier de l'Ordre National du Mérite de la France (1996); Chevalier de l'Ordre National du Lion du Senegal (1999); Chevalier de l'Ordre National du Tchad (1999); Officier de l'Ordre National du Lion du Senegal (2002); Officier de l'Ordre du Mérite du Senegal (2016); and Officier de l'Ordre du Mérite Universitaire du Congo-Brazzaville (2020).



Narmada P. Gupta  
India

## SIU-Albert Schweitzer International Teaching Award 2021

### **Narmada P. Gupta, MD, D.Sc, FAMS**

After his medical school and post-graduation in surgery, Dr. Gupta specialized in urology and joined the faculty of the Department of Urology at the All India Institute of Medical Sciences (AIIMS) in 1979. He rose to the position of professor and chairman from 1998 to 2010, and currently works as Professor Emeritus Urology, at Medanta – The Medicity hospital in Gurgaon, India.

He has published more than 320 scientific papers in various national and international journals, written six books on urology, contributed chapters to nine books, and produced 28 teaching videos. He is a teacher par excellence and has trained over 120 M.Ch., postgraduates in urology who are now providing quality urology care all over India; some even occupy professorial chairs in the United States. Under his leadership, the Department of Urology at AIIMS was recognized as a centre for training for the Société Internationale d'Urologie (SIU) and the Endourological Society.

He was past president of Urological society of India and Urological Association of Asia. He has received many awards and honors, notably the Dr. B. N. Oration by the Society of Surgeons of Nepal (2006), the Golden Jubilee Oration and Gold Medal by the Delhi chapter of the ASI, (2007), the Award to Eminent Men for Distinguished Achievement of the Highest Order by the Indian Medical Association (IMA) (2007), the Himadri Sarkar Memorial Oration by the USI (2009), the Urology Gold Medal by the USI (2009), the Lifetime Achievement Award by the North Zone Chapter of the USI (2010), and the Dr. M. M. Malla Oration by the Nepal Chapter of the International College of Surgeons (2014).

Dr. Gupta was conferred the Fellowship of the Academy of Medical Sciences (FAMS) in 1997 and an honorary doctorate of science (D. Sc) by Rani Durgavati Vishwavidyalaya in 2009 for his contribution to the science of urology. He was awarded the Ranbaxy Research Award in 2009 for his contribution to research in urology.

In 2007, Dr. Gupta was awarded the Padma Shree, the highest civilian award, by the government of India in recognition of his distinguished services in urology to the nation and Dr. B.C.Roy national award by Medical Council of India in 2005.

# Distinguished Career Award 2021



Hassan Abol-Enein  
Egypt

### **Hassan Abol-Enein, MD, PhD**

Hassan Abol-Enein is a professor of urology in the Urology and Nephrology Center of Mansoura University in Egypt. He earned his PhD in urology at Radboud University Nijmegen in the Netherlands in 2001.

Prof. Abol-Enein has more than 173 publications in peer-reviewed journals and is the innovator of many techniques in reconstructive urology for reflux prevention and continent outlet. He is the former director and chairman of the Urology and Nephrology Centre of Mansoura University in Egypt. Dr. Abol-Enein is a reviewer for many international journals and an active member in the Arab Journal of Urology editorial board.

He is a member in all international urological societies, former president of the Arab Association of Urology (AAU), and the head of the scientific office of the AAU. He has been a visiting professor to universities in 16 countries, a visiting surgeon for live surgery and workshops in more than 14 countries, and has won many national and international prizes.



Margit Fisch  
Germany

### **Margit Fisch, MD, FEAPU, FEBU**

Prof. Margit Fisch is a Fellow of the European Board of Urology (FEBU) and a Fellow of the European Academy of Paediatric Urology (FEAPU). She trained with Prof. Rudolf Hohenfellner and Prof. Joachim Thüroff in Mainz, Germany. In 2000, she moved to the AK Harburg in Hamburg and, two years later, became the director of the Department of Urology and Pediatric Urology. Her major scientific interests are reconstructive urology—especially urethral reconstruction and urinary diversion—and pediatric urology.

Prof. Fisch was president of the Society of Genitourinary Reconstructive Surgeons (GURS) and the European Society of Genito-Urinary Surgeons (ESGURS). She is a member of the American Academy of Genitourinary Surgeons (AAGUS), the Association of Academic European Urologists (AAEU), the European Association of Paediatric Urology (ESPU), and the Society of Pediatric Urology Surgeons (SPUS).

She has published more than 300 papers and book chapters; more than 90 are as first author. Every three years, she organizes the International Meeting on Reconstructive Urology (IMORU). Since 2008, she has been the first female chair of a urology department, at the University Medical Center Hamburg-Eppendorf in Germany. Starting on September 18th, 2021, Prof. Fisch is the president of the German Association of Urology.

# Distinguished Career Award 2021



Ateş Kadioğlu  
Turkey

### **Ateş Kadioğlu, MD/FECSM**

Ateş Kadioğlu graduated from the Istanbul Faculty of Medicine in 1983. He served as a resident until 1990, and then as clinical instructor at the same faculty. He became associate professor in 1994, and then professor in 2000. Prof. Kadioğlu served as the president of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the honorary president of the Turkish Society of Andrology and the head of the Division of Andrology in the Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. He is currently vice president of the Turkish Association of Urology, coordinator of the Turkish Academy of Urology, and editor-in-chief of the Turkish Journal of Urology.

Prof. Kadioğlu served as a vice dean of the Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the European Association of Urology (EAU).

He contributed as a reviewer to the journals European Urology, Journal of Sexual Medicine, Andrology, Asian Journal of Andrology, Andrologia, and World Journal of Clinical Urology. He is a board member of the EAU Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU on October 1 and 2, 2010, and the European Society for Sexual Medicine Congress (ESSM) from January 29 to February 2, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He also participated in the Peyronie's Disease Committee in the 4th International Erectile and Sexual Function consultation.

# Distinguished Career Award 2021



Alexey G. Martov  
Russia

## Alexey G. Martov, MD, PhD

Alexey G. Martov, MD, PhD, Honored Doctor of Russia, is a professor and chairman in the Department of Urology of the Federal Medical-Biological Agency; professor of urology of the Lomonosov Moscow State University Medical Centre; and head of the Urology Department of the D. D. Pletnev Moscow City Hospital.

In 1988, Dr. Martov started as the head of the Endourology Department at the Institute of Urology and, by 2006, he was the institute's vice-president. In 1993, he earned his PhD degree in "Endourological Treatment of Upper Urinary Tract Diseases." In 2006, he was named p.t. head of Urology Department at D. D. Pletnev Moscow City Hospital and professor of urology at the Russian Medical Academy of Postgraduate Education. In 2012, he became p.t. professor and chairman of the Department of Urology of the Federal Medical-Biological Agency, Russia, and in 2018 he was named professor and leading researcher at the Lomonosov Moscow State University Medical Centre.

Dr. Martov is a founding member and president of the Russian Endourology and New Urotechnology Society, vice-president of the Russian Urology Society, and an honorary member of the Russian, Georgian, and Azerbaijan Urology Association. He is co-editor of the Russian journal Urology.

Dr. Martov's specializations and interests include endourology, benign prostatic hyperplasia (BPH), stone disease, and uro-oncology. He has written more than 400 scientific publications in PubMed-cited journals, 15 books, and 35 books chapters, and produced three educational CDs for urologists on the topics of endourology, BPH, and prostate cancer. He has also received numerous international invitations for live surgery meetings, presentations, workshops, congresses, and teaching events in Russia, countries of the former Soviet Union, Germany, France, Austria, Switzerland, Turkey, and Sweden, among others.

# SIU-Innovators Award 2021



Jeremy Y. C. Teoh  
Hong Kong

## **Jeremy Y. C. Teoh**, MBBS, FRCSEd, FCSHK, FHKAM

Dr. Jeremy Teoh joined the Chinese University of Hong Kong as an assistant professor in 2016, and he has been the assistant dean (external affairs) of the Faculty of Medicine since 2020.

In 2010, Dr. Teoh started research work in prostate cancer under the supervision of Professor Anthony Ng at the Chinese University of Hong Kong. He has published extensively on the adverse effects of androgen deprivation therapy in the Asian population. He also found that, among the different modalities of androgen deprivation therapy, bilateral orchidectomy was associated with the highest risk of cardiovascular events.

With time, Dr. Teoh has developed an immense interest in bladder cancer. In a randomized trial, he showed that bipolar transurethral resection of bladder tumour (TURBT) was able to achieve a higher detrusor sampling rate than monopolar TURBT. He also developed the global consensus statement on en bloc resection of bladder tumour (ERBT), which has become the standard of reference for ERBT worldwide. He is the Asian national coordinator for the RESECT study, which is the largest-ever global study evaluating the quality of TURBT. He is also an active member of the European Association of Urology Young Academic Urologists (EAU-YAU) and the Asian Robot-Assisted Radical Cystectomy Consortium.


Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine. With UroSoMe, he published a major survey on the impact of COVID-19 on urological services worldwide. He is the social media co-chair of the Société Internationale d'Urologie (SIU) Innovators, and the social media editor of the SIU Journal. Dr. Teoh has received numerous research grants, for total funding of more than €3.3 million. He has published more than 140 articles in peer-reviewed journals such as European Urology, Journal of Urology, and BJU International. He is currently the chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong, and he has been the director of the Lions Kidney Educational Centre and Research Foundation since 2016.


# Distinguished Partner Award 2021



## Coloplast Interventional Urology

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions, including stress urinary incontinence, pelvic organ prolapse, Peyronie's disease, kidney stones, and erectile dysfunction. Products include Titan<sup>®</sup> Touch, Restorelle<sup>®</sup>, Altis<sup>®</sup>, and ReTrace<sup>®</sup>.





0700				0700
0730				0730
0800	<b>0730–0900</b> <b>IC-01: Instructional Course 01</b> PCNL Tips/Tricks and Pitfalls <i>ROOM: Dubai CD</i>	<b>0755–0900</b> <b>MC-01: Master Class 01</b> Advanced Kidney Cancer <i>ROOM: Sheikh Rashid A</i>	<b>0800–0900</b> <b>MC-02: Master Class 02</b> Refractory Overactive Bladder Syndrome <i>ROOM: Sheikh Maktoum D</i>	0800
0830				0830
0900	<b>0900–1200</b> <b>INN - Prostate MRI Reading and Fusion Biopsy Hands On Training Course</b> <i>ROOM: Sheikh Rashid B</i> Pre-registration required.		<b>0900–1045</b> <b>PL-01: Plenary 01</b> <i>ROOM: Sheikh Rashid CDF</i>	0900
0930				0930
1000				1000
1030				1030
1100		<b>1045–1245</b> <b>TIPS-02: SIU Tips and Tricks Session</b> <i>ROOM: Dubai AB</i>	<b>1045–1115</b> <b>Coffee Break</b> <i>ROOM: EXHIBIT HALL - SHEIKH RASHID E</i>	1100
1130			<b>1115–1245</b> <b>HT-01: Hot Topics 01</b> Harnessing Artificial Intelligence (AI) in Urology <i>ROOM: Dubai CD</i>	1130
1200			<b>1115–1245</b> <b>HT-02: Hot Topics 02</b> PSMA Theranostics <i>ROOM: Ras Al Khaimah</i>	1200
1230				1230
1300	<b>1245–1415</b> <b>Lunch Break</b> <i>ROOM: Exhibit Hall - Sheikh Rashid E</i>	<b>1245–1315</b> <b>SYMP-21 - Focal HIFU Therapy in Prostate Cancer: Practice Changes on the Horizon?</b> <i>ROOM: Sheikh Maktoum BC</i>		1300
1330				1330
1400		<b>1400–1700</b> <b>SYMP-20: Emirates Urological Society (EUS) Symposium</b> <i>ROOM: Sheikh Rashid CDF</i>	<b>1415–1545</b> <b>IC-06: Instructional Course 06</b> Minimally Invasive PCNL (Mini-PCNL): The Way Forward <i>ROOM: Abu Dhabi A</i>	1400
1430			<b>1415–1545</b> <b>IC-07: Instructional Course 07</b> Focal Therapy for Locoregional or Oligometastatic Recurrence of Prostate Cancer <i>ROOM: Dubai CD</i>	1430
1500				1500
1530				1530
1600	<b>1545–1615</b> <b>Coffee Break</b> <i>ROOM: Exhibit Hall - Sheikh Rashid E</i>			1600
1630			<b>1615–1745</b> <b>IC-08: Instructional Course 08</b> Case Based Discussions in Neuro-urology <i>ROOM: Ras Al Khaimah</i>	1630
1700			<b>1615–1745</b> <b>IC-09: Instructional Course 09</b> Complex Penile and Urethral Reconstruction in Adults with Prior Hypospadias or Epispadias <i>ROOM: Dubai CD</i>	1700
1730				1730
1800				1800

0700						0700
0730						0730
0800						0800
0830						0830
0900						0900
0930						0930
1000						1000
1030						1030
1100	<b>1045–1115</b> <b>Coffee Break</b> <i>ROOM: Exhibit Hall - Sheikh Rashid E</i>					1100
1130	<b>1115–1245</b> <b>IC-03: Instructional Course 03</b> Imaging-Guided Biopsy Diagnostic Pathway in Prostate Cancer <i>ROOM: Abu Dhabi B</i>	<b>1115–1245</b> <b>IC-04: Instructional Course 04</b> Novel BPH Therapies – Review of Technologies and Practical Instruction (Laser EEP, UroLift, Rezum, Aquablation, Stents) <i>ROOM: Abu Dhabi A</i>	<b>1115–1245</b> <b>JS-01: Joint SIU-Endourology Session</b> <i>ROOM: Sheikh Maktoum D</i>	<b>1115–1245</b> <b>JS-02: Joint SIU International Society of Reconstructive Urology (ISORU) Session</b> <i>ROOM: Sheikh Rashid A</i>	<b>1115–1245</b> <b>MP-01: Moderated ePoster Session 01</b> Bladder Cancer <i>ROOM: Sharjah D</i>	1130
1200						1200
1230						1230
1300						1300
1330						1330
1400						1400
1430	<b>1415–1545</b> <b>MV-01: Master Videos 01</b> Genitourinary Fistulae <i>ROOM: Sheikh Rashid A</i>	<b>1415–1545</b> <b>MP-03: Moderated ePoster Session 03</b> Infections & Inflammatory Disease <i>ROOM: Dubai AB</i>	<b>1415–1715</b> <b>INN: SIU Innovators' Symposium</b> <i>ROOM: Sheikh Maktoum D</i>			1430
1500		<b>MVP-01: Moderated Video Session 01</b> Miscellaneous, Pediatric Urology, Reconstruction <i>ROOM: Sharjah D</i>				1500
1530						1530
1600						1600
1630	<b>1615–1745</b> <b>MV-02: Master Videos 02</b> Endoscopic Surgery for BPH: Compare and Contrast <i>ROOM: Sheikh Rashid A</i>	<b>1615–1745</b> <b>IS-01 (end 1750)</b> <b>Interactive Session 01</b> <b>Open Surgery in 2021: When and Why?</b> <i>ROOM: Abu Dhabi B</i>				1630
1700						1700
1730						1730
1800						1800

0700	0700–0800 SIU General Assembly ROOM: Abu Dhabi B			0700
0730		0730–0900 IC-11: Instructional Course 11 Bleeding Complications of PCNL - Prevention & Management ROOM: Ras Al Khaimah	0730–0900 IC-12: Instructional Course 12 Tools to Make Caring for Pelvic Pain Easier and More Successful for the Urologist ROOM: Umm Al Quwain	0730
0800	0800–1600 NURS: 6th SIU Global Nurses’ Educational Symposium ROOM: Dubai CD			0800
0830				0830
0900		0900–1045 PL-02: Plenary 02 ROOM: Sheikh Rashid CDF	0900–1030 DEMO: Demo Session: Tips and Tricks in fURS Pre-registration required ROOM: Abu Dhabi B	0900
0930				0930
1000				1000
1030				1030
1100		1045–1115 Coffee Break ROOM: Sheikh Rashid E		1100
1130			1115–1245 HT-03: Hot Topics 03 Future of Urology - Next 20 Years ROOM: Abu Dhabi A	1130
1200				1200
1230				1230
1300		1245–1415 Lunch Break ROOM: Exhibit Hall - Sheikh Rashid E	1245–1415 SYMP-22: Luncheon Symposium: Immunotherapy in MIUC: Current Practices and Future Perspectives ROOM: Sheikh Maktoum BC	1300
1330				1330
1400				1400
1430		1415–1545 CO-01: Controversies in Urology 01 High-Risk Prostate Cancer, Adjuvant & Salvage Therapies ROOM: Sheikh Maktoum D	1415–1545 CO-02: Controversies in Urology 02 Sexual Dysfunction and Infertility: What Works and What Does Not? ROOM: Ras Al Khaimah	1430
1500				1500
1530				1530
1600		1545–1615 Coffee Break ROOM: Exhibit Hall - Sheikh Rashid E		1600
1630		1615–1745 IC-16: Instructional Course 16 Testosterone, the Prostate and Cardiovascular Disease: Addressing Safety and Efficacy in Testosterone Replacement Therapy ROOM: Ras Al Khaimah	1615–1745 IC-17: Instructional Course 17 Risk Reducing Surgery in Urology: For Whom, When and How? ROOM: Umm Al Quwain	1630
1700				1700
1730				1730
1800				1800
			1615–1745 IS-02: Interactive Session 02 Renal Transplantation Frontiers: Donation after Cardiac Death (DCD) Kidneys - All You Wanted to Know but Were Afraid to Ask! ROOM: Sheikh Maktoum D	

0700					0700
0730					0730
0800	<b>0800–0900</b> <b>MC-03: Master Class 03</b> Geriatric Urology <i>ROOM: Abu Dhabi A</i>				0800
0830					0830
0900					0900
0930					0930
1000					1000
1030					1030
1100					1100
1130	<b>1115–1245</b> <b>IC-02: Instructional Course 02</b> Orthotopic Reconstruction: How to Improve Outcomes <i>ROOM: Umm Al Quwain</i>	<b>1115–1245</b> <b>IC-14: Instructional Course 14</b> Nuestros Trucos Técnicos en Cirugía Uretral (Course in Spanish) [Our Technical Tricks in Urethral Surgery] <i>ROOM: Ras Al Khaimah</i> 	<b>1115–1245</b> <b>JS-03: Joint SIU-International Continence Society (ICS) Session</b> <i>ROOM: Sheikh Rashid A</i>	<b>1115–1245</b> <b>JS-04: Joint SIU-Society of Urologic Robotic Surgeons (SURS) Session</b> <i>ROOM: Sheikh Maktoum D</i>	1130
1200					1200
1230					1230
1300					1300
1330					1330
1400					1400
1430	<b>1415–1545</b> <b>MV-03: Master Videos 03 - Complex Upper-tract Reconstructive Surgery</b> <i>ROOM: Sheikh Rashid A</i>	<b>1415–1545</b> <b>RF-01: Residents' Forum - Moderated ePoster Session</b> <i>ROOM: Abu Dhabi A</i>	<b>1415–1545</b> <b>MP-04: Moderated ePoster Session 04 - BPO/LUTS, MIS, Robotics</b> <i>ROOM: Abu Dhabi B</i>		1430
1500					1500
1530					1530
1600					1600
1630	<b>1615–1745</b> <b>JS-05: Joint SIU-Society of Genitourinary Reconstructive Surgeons (GURS) Session</b> <i>ROOM: Sheikh Rashid CDF</i>	<b>1615–1745</b> <b>MV-04: Master Videos 04</b> Laparoscopy Sans the Robot <i>ROOM: Sheikh Rashid A</i> 	<b>1615–1745</b> <b>MP-06: Moderated ePoster Session 06 - Stones</b> <i>ROOM: Abu Dhabi A</i>	<b>1615–1745</b> <b>MP-05: Moderated ePoster Session 05 - Kidney, Ureter, Adrenals</b> <i>ROOM: Abu Dhabi B</i>	1630
1700					1700
1730					1730
1800					1800

# Join the International Urology Community in Montreal CANADA

Save the date!  
November 9-13, 2022







SIU  
Around the  
**WORLD**  
**MONTREAL** 2022

42nd Congress of the  
Société Internationale  
d'Urologie  
Palais des congrès de Montréal

[www.siu-urology.org](http://www.siu-urology.org)

in f t #SIUWorld #SIU2022

0730	<b>0730–0900</b> <b>IC-18: Instructional Course 18</b> Advanced Ureteroscopy <i>ROOM: Ras Al Khaimah</i>	<b>0730–0900</b> <b>IC-19: Instructional Course 19</b> Técnicas Quirúrgicas para HPB: Paso a Paso (Course in Spanish) [Surgical Techniques forBPH: Step by Step] <i>ROOM: Abu Dhabi B</i>		0730	
0800			<b>0800–0900</b> <b>MC-05: Master Class 05</b> - Biomarkers in Cancer <i>ROOM: Sheikh Rashid A</i> 	<b>0800–0900</b> <b>MC-07: Master Class 07</b> - Complex Reconstruction (Lower-tract) <i>ROOM: Dubai CD</i> 	0800
0830			<b>MC-06: Master Class 06</b> - Undescended Testis (UDT) <i>ROOM: Abu Dhabi A</i>		0830
0900	<b>0900–1045</b> <b>PL-03: Plenary 03</b> <i>ROOM: Sheikh Rashid CDF</i> 				0900
0930					0930
1000					1000
1030					1030
1100	<b>1045–1115</b> <b>Coffee Break</b> <i>ROOM: Sheikh Rashid E</i>				1100
1130	<b>1115–1245</b> <b>MP-07: Moderated ePoster</b> Session 07 - Prostate Cancer <i>ROOM: Ras Al Khaimah</i> <b>MP-08: Moderated ePoster</b> Session 08 - Reconstruction <i>ROOM: Abu Dhabi A</i>	<b>1115–1245</b> <b>JS-06: Joint SIU-Society of Urologic Oncology (SUO)/EAU Section of Oncological Urology (ESOU)</b> <i>ROOM: Abu Dhabi B</i>			1130
1200					1200
1230					1230
1300	<b>1245–1415</b> <b>Lunch Break</b> <i>ROOM: Sheikh Rashid E</i>				1300
1330					1330
1400					1400
1430	<b>1415–1545</b> <b>MVP-02: Moderated Video Session 02</b> Kidney and Ureter/ Benign Diseases, Minimally Invasive Surgery/Robotics, Stones <i>ROOM: Ras Al Khaimah</i>	<b>1415–1545</b> <b>MV-05: Master Videos 05</b> Robotics: State of the Art <i>ROOM: Abu Dhabi B</i>	<b>1415–1545</b> <b>MV-06: Master Videos 06</b> RIRS and PCNL <i>ROOM: Sheikh Rashid A</i> 	<b>1415–1545</b> <b>MP-09: Moderated ePoster Session 09</b> Andrology, Infertility, Penis/Testis/ Urethra, Trauma <i>ROOM: Abu Dhabi A</i>	1430
1500					1500
1530					1530
1600					1600

## 0730–1500

### LS: Semi-Live Surgery

#### Co-Chairs

Jean de la Rosette, Turkey  
Thomas Herrmann, Switzerland  
Rafael Sanchez-Salas, Canada

**ROOM: Sheikh Rashid CDF**

## 0730–0900

### Focal Therapy and Imaging

#### Lead Moderator

Mauro Gacci, Italy

#### Moderators

Jürgen Futterer, The Netherlands  
Sung Kyu Hong, South Korea  
Rahim Horuz, Turkey  
Ka Lun Lo, China  
Rafael Tourinho-Barbosa, Brazil

#### Surgeries:

**Micro-Ultrasound/MRI Fusion Biopsy with Real Time Visualization**

Petr Macek, France

**Focal One Treatment**

Franck Bladou, France

**IRE Focal Treatment**

José Luis Domínguez-Escrig, Spain

## 0900–1100

### Reconstructive Surgery

#### Lead Moderator

Reynaldo Gómez, Chile

#### Moderators

Avelino Fraga, Portugal  
Serigne Magueye Gueye, Senegal  
Kurt McCammon, United States

#### Surgeries

**Penile Implant**

Koenraad van Renterghem, Belgium

**Urethral Repair**

Evelyn Mmapula Moshokoa, South Africa

**Peyronie's Surgery**

Ates Kadioğlu, Turkey

**Fistula Repair**

Tamsin Greenwell, United Kingdom

## 1100–1300

### Endourology

#### Lead Moderator

Mélanie Aubé-Peterkin, Canada

#### Moderators

Abdullatif Al-Terki, Kuwait  
Anastasios Anastasiadis, Greece  
Vincent De Coninck, Belgium  
Sanjay Khadgi, Nepal

#### Surgeries

**Mini PCNL plus US**

Madhu S Agrawal, India

**RIRS with Holmium Lithotripsy**

Leye Ajayi, United Kingdom

**TUEP**

Thomas Herrmann, Switzerland

**Aquablation**

Mihir Desai, United States

## 1300–1500

### Uro-oncology

#### Lead Moderator

Pilar Laguna, Turkey

#### Moderators

Piotr Chlosta, Poland  
Mahesh R. Desai, India  
Andrés Hernández-Porras, Mexico  
Richard Mallet, France

#### Surgeries

**UTUC**

Olivier Traxer, France

**En-bloc TURBT**

Jeremy Yuen-Chun Teoh, Hong Kong

**Robotic Partial Nephrectomy**

Azhar, Saudi Arabia

**Robotic Cystectomy**

Mevlana Derya Balbay, Turkey

#### Learning Objectives

At the end of this session, attendees will be able to:

- Recognize important considerations in the surgical techniques for reconstructive surgery, such as penile prosthesis, male sling, etc., and select the best reconstructive approach for complex cases
- Learn from other professionals' clinical experience with surgical conditions, including clinical management, multidisciplinary care, and clinical outcomes
- Demonstrate practical knowledge related to instrumentation techniques for upper and lower urinary tract cases via surgical and emerging minimally invasive approaches
- Learn about emerging procedures in the area of robotics in oncology
- Demonstrate the use of imaging to perform targeted and systematic biopsies
- Learn about minimal invasive treatment options for localized prostate cancer using focal therapies

*This session is supported by SIU Corporate Sponsors: Coloplast, Karl Storz.*

*Congress Contributors: AngioDynamics, EDAP TMS, Exact Imaging, Gulf Medical, and Procept BioRobotics.*

## 0900-1030

### DEMO - Tips and Tricks in fURS

#### Chair

Wissam Kamal, Saudi Arabia

**ROOM: Abu Dhabi B**

#### Faculty

Saeed Bin Hamri, Saudi Arabia

Mudhar Nazar Hassan, United Arab Emirates

*Pre-registration is required for this session.*

This session will focus more on endourological procedures (RIRS and PCNL) in terms of instrumentation, technique and tips and tricks.

#### Learning Objectives

- Assess indications of each technique (PCNL and RIRS)
- Compare instrumentation for each technique (disposable vs. reusable equipment)
- Recognize the basics of endoscope manipulation and laser applications
- Understand the principles of management of endourological complications

*This session is supported by SIU Corporate Sponsor Coloplast.*

## 0900-1200

### INN-01: Prostate MRI Reading and Fusion Biopsy Hands On Training Course

#### Co-Chairs

Christof Kastner, United Kingdom

Tristan Barrett, United Kingdom

**ROOM: Sheikh Rashid B**

#### Faculty

Jürgen Futterer, The Netherlands

*Pre-registration is required for this session.*

#### 0900-0905

### Welcome and Introduction to Prostate Cancer Diagnostics and the Role of MRI

Christof Kastner

#### 0905-01040

### MRI Workshop

Tristan Barrett

#### 0905-0917

### Tutorial: Prostate MRI and PI-RADS

#### 0917-0922

### DynaCAD Introduction

Presented by Philips

#### 0922-0957

### Hands-On: MRI Case Analysis DynaCAD - Basic

#### 0957-1005

### Tutorial: Pearls & Pitfalls of Reading and Reporting

#### 1005-1040

### Hands-On: MRI Case Analysis DynaCAD - Basic-Item

#### 1040-1055

### Integration of MRI and Fusion Biopsy into the Diagnostic Pathway

Christof Kastner

#### 1055-1130

### Biopsy Workshop

Christof Kastner

#### 1055-1105

### Tutorial: Biopsies Using Prostate MRI

#### 1105-1130

### Live & On-Screen Demo by Industry: Advanced Biopsy Equipment

#### 1130-1145

### Value and Use of MRI Based Assessment in Treatment Decision and Surveillance of Prostate Cancer

Jürgen Futterer

#### 1150-1200

Discussion and Finish

#### Learning Objectives

- Recall key features of systematic prostate MRI reading according to PI-RADS standards
- Read and report basic and intermediate level prostate MR imaging with confidence
- Recognize the technical features and capabilities of prostate biopsy and fusion technology using MR imaging for targeting
- Identify the key requirements to safely integrate MR imaging into the prostate diagnostic pathway

*This session is supported by SIU Congress Contributors: Koelis, MedCom and Philips.*

## 1115-1245

### IC-04: Instructional Course 04

#### Novel BPH Therapies – Review of Technologies and Practical Instruction (Laser EEP, UroLift, Rezum, Aquablation, Stents)

##### Chair

Dean Elterman, Canada

**ROOM: Abu Dhabi A**

#### 1115-1120

##### Introduction to Novel BPH Therapies

Dean Elterman, Canada

#### 1120-1132

##### Laser Transurethral Endoscopic Enucleation of the Prostate (EEP)

Vincent Misrai, France

#### 1132-1136

##### Q&A

Vincent Misrai, France

#### 1136-1148

##### UroLift

Dean Elterman, Canada

#### 1148-1152

##### Q&A

Dean Elterman, Canada

#### 1152-1204

##### Rezum

Vineet Gauhar, Singapore

#### 1204-1208

##### Q&A

Vineet Gauhar, Singapore

#### 1208-1220

##### Aquablation

Enrique Rijo, Spain

#### 1220-1224

##### Q&A

Enrique Rijo, Spain

#### 1224-1236

##### Stents

Dean Elterman, Canada

#### 1236-1240

##### Q&A

Dean Elterman, Canada

#### 1240-1245

##### Closing Remarks

Dean Elterman, Canada

##### Learning Objectives:

At the end of this session, attendees will be able to:

- Understand the mechanism of action and technique for each of the novel BPH therapies
- Select the best patients for each procedure type based upon patient and prostate characteristics

- Gain knowledge of the clinical data supporting the use of each modality
- Understand best-practice technique for each modality based upon the literature and expert opinion
- Gain an appreciation for the challenges encountered and troubleshooting for each technology
- Appreciate the “tips & tricks” provided by the experts for performing these novel BPH therapies

*This session is supported by SIU Congress Contributor: Teleflex.*

## 1245-1315

### Luncheon Symposium: Focal HIFU Therapy in Prostate Cancer: Practice Changes on the Horizon?

##### Chair

Rafael Sanchez-Salas, Canada

**ROOM: Sheikh Maktoum BC**

##### On-Site Moderator

Franck Bladou, Canada

##### Faculty

Pascal Rischmann, France

Martin Schostak, Germany

##### Learning Objectives:

At the end of this session, attendees will be able to:

- Review the current implementation of focal HIFU therapy for localized prostate cancer, with a focus on differences in HIFU adoption in different countries.
- Examine alternative focal therapy approaches currently used in the clinical practice to manage localized disease.
- Analyze advances in HIFU technology and their impact on treatment decision-making, with emphasis on oncologic control and patient quality of life.
- Discuss current challenges limiting the adoption of focal HIFU therapy in the clinical practice, including differences in guideline recommendations.

*This session is supported by SIU Congress Contributor: EDAP TMS.*

## 1400-1700

### Symposium 20: Emirates Urological Society (EUS) Programme

##### Co-Chairs

Abdulqadir Alzarooni, United Arab Emirates

Yasser Farahat, United Arab Emirates

**ROOM: Sheikh Rashid CDF**

#### 1400-1405

##### Welcome Remarks

Abdulqadir Alzarooni, United Arab Emirates

Jean de la Rosette, Turkey

Yasser Farahat, United Arab Emirates

## Part 1 - Miniaturization in Endourology

1405-1415

### Miniaturization in PCNL: CON

Noor Buchholz, United Arab Emirates

1415-1425

### Miniaturization in PCNL: PRO

Sanjay Khadgi, Nepal

1425-1435

### Miniaturization in FURS: Is it The Way to Go?

Saeed Bin Hamri, Saudi Arabia

1435-1445

### Miniaturization in Stone Fragments: Is Dusting the Best Choice?

Rabii Madi, United Arab Emirates

1445-1450

### Expert Comments

Iyad Emad, United Arab Emirates

Jean de la Rosette, Turkey

Yasser Farahat, United Arab Emirates

## Part 2 - Men's Health Current and Future Challenges

1450-1500

### COVID 19 & Sexual Dysfunction: The Untold Story

Vipin Bhatia, United Arab Emirates

1500-1510

### Updates in the Management of ED & BPH/LUTS

Muhammad Bulbul, Lebanon

1510-1520

### Anatomical Considerations of IPP Placement: Pitfalls you Can Avoid

Daniar Osmonov, Germany

1520-1530

### Penile Lengthening Strategies at Time of IPP

Steven Wilson, United States

1530-1535

### Expert Comments

Manaf Al Hashimi, United Arab Emirates

Mohamed Elkhoully, United Arab Emirates

Abdulqadir Alzarooni, United Arab Emirates

## Part 3 - BPH/LUTS: Best Clinical Practice

1535-1545

### Recent Recommendation in the Management of Male LUTS

Stavros Gravas, Cyprus

1545-1555

### MIST of BPH

Dean Elterman, Canada

1555-1605

### Echolaser Transperineal Ablation of the Prostate in Outpatient Setting

Alessandro Bertaccini, Italy

Debora Marchiori, Italy

1605-1615

### Post Prostatectomy ED/ incontinence: Surgical Tips & Tricks

Valentin Pavlov, Russia

1615-1620

### Expert Comments

Wael Toson Abdelsalam, United Arab Emirates

Mohsen Elmekresh, United Arab Emirates

Yaser Saeedi, United Arab Emirates

## Part 4 - Updates in Prostate Cancer

1620-1630

### MRI Imaging of Prostate in Clinical Practice

Waleed Hassen, United Arab Emirates

1630-1640

### PET Scanning in Prostate Cancer: Current Recommendation(s)

Hidayath Ansari, United Arab Emirates

1640-1650

### Patient Selection for Focal Therapy

Laurence Klotz, Canada

1650-1700

### Management Updates in mHSPC

Jawaher Ansari, United Arab Emirates

1700-1705

### Expert Comments

Hosam Al-Qudah, United Arab Emirates

Ali Thwaini, United Arab Emirates

Waleed Hassen, United Arab Emirates

1705-1710

### Closing Remarks

Abdulqadir Alzarooni, United Arab Emirates

Yasser Farahat, United Arab Emirates

*This session is supported by EUS corporate sponsors:*

*Pierre Fabre and SAJA*

*Silver Sponsor: Pusen*

*Bronze Sponsors: Aramed, Gulf Drug & Olympus, Janssen and Lilly*

1615-1745

## MV-02: Master Videos 02 - Endoscopic Surgery for BPH: Compare and Contrast

### Co-Chairs

Athanasios Papatsoris, Greece

Anil Kumar Varshney, India

### ROOM: Sheikh Rashid A

1615-1630

### Aquablation

Vincent Misrai, France

## 1630–1645

### **Urolift: Minimally Invasive Surgical Procedures for LUTS due to BPO: Focus on PUL**

Mauro Gacci, Italy

## 1645–1700

### **Various Endoscopic Enucleation Procedures in Europe**

Javier Sanchez Macias, Spain

## 1700–1715

### **Enucleation by Holmium Laser (HoLEP)**

Anil Kumar Varshney, India

## 1715–1730

### **BipolEP**

Athanasios Papatsoris, Greece

Dimitrios Staïos, Greece

## 1730–1740

### **Q&A + Panel Discussion**

Mauro Gacci, Italy

Javier Sanchez Macias, Spain

Vincent Misrai, France

Athanasios Papatsoris, Greece

Dimitrios Staïos, Greece

Anil Kumar Varshney, India

## 1740–1745

### **Take-home Message**

Athanasios Papatsoris, Greece

Anil Kumar Varshney, India

### **Learning Objectives:**

At the conclusion of this course, attendees will be able to:

- Discuss the place of endoscopic surgeries in the overall management of BPH
- Compare various indications, contraindications, technical details and know how to do these procedures
- Learn where they can go wrong and how to minimize complications
- Gain tips to provide better outcomes
- Understand the limitations and scenarios when not to do these operations
- Highlight efficacy parameters, safety concerns, durability, versatility, cost-effectiveness, learning and mentoring

*This session is supported by SIU Congress Contributor: Teleflex.*

## 0800-1600

### NURS: 6th SIU Global Nurses' Educational Symposium

#### Co-Chairs

Hussam Al Nusair, United Arab Emirates  
Amparo Gudrun Camacho, United States

**ROOM: Dubai CD**

#### 0800-0805

##### Welcome

Hussam Al Nusair, United Arab Emirates  
Amparo Gudrun Camacho, United States

#### 0805-0830

##### Diagnosis and Treatment of Bladder Cancer

Waleed Hassen, United Arab Emirates

#### 0830-0850

##### Ostomy Management

Vashti Livingston, United States

#### 0850-0910

##### ERAS: Enhanced Recovery After Surgery

Corey Weinstein, United States

#### 0910-0935

##### Compliance with Erectile Dysfunction Treatment in Men with Prostate Cancer

Christian Nelson, United States

#### 0935-1000

##### Case Study and Clinicians' Experiences: Nursing Support for Patients with Sexual Dysfunction

Samantha Strumeier, United States

#### 1000-1015

##### Infection Control for Penile Implantation

Monica Chan, United Arab Emirates

#### 1015-1030

##### Break and ePoster Poster Viewing

#### 1030-1055

##### BPH/LUTS Treatment

Jaspreet S. Sandhu, United States

#### 1055-1105

##### Nursing Considerations for Patients with Urinary Symptoms

Lydia Nahorniak, United States

#### 1105-1115

##### Nursing Practice Related to Intermittent Catheterization Evidence-Based Practice

Marcerey Sison Quejada, United Arab Emirates

#### 1115-1120

##### Q&A

Lydia Nahorniak, United States  
Marcerey Sison Quejada, United Arab Emirates

#### 1120-1135

##### Abstract Presentations

##### Moderators

Amparo Gudrun Camacho, United States  
Mariezi Fonbuena, United Arab Emirates

#### 1135-1150

##### Case Study: Prostate Cancer Patient Care

Amparo Gudrun Camacho, United States

#### 1200-1250

##### Break

#### 1250-1315

##### The Role of Imaging and Novel Biomarkers to Guide Active Surveillance

Behfar Ehdaie, United States

#### 1315-1340

##### Considerations When Performing Prostate Biopsies

Kenny (Xin) Lin, United States

#### 1340-1350

##### Urodynamic Setup

Abigail Rome Bibe, United Arab Emirates

#### 1350-1400

##### Interpretation and Artifacts

Dean Elterman, Canada

#### 1400-1410

##### Neuromodulation

Dean Elterman, Canada

#### 1410-1415

##### Q&A

Dean Elterman, Canada

#### 1415-1440

##### Therapeutic Modalities and Management of Complex Stone Disease

Daniel Pérez-Fentes, Spain

#### 1440-1455

##### Operating Room Settings for Stone Surgery (PCNL, Ureteroscopy with Lithotripsy)

Rogelio Silverio, United Arab Emirates

#### 1455-1510

##### Laser Safety in Surgery - General Safety and Specific Requirements in OT

Rogelio Silverio, United Arab Emirates

#### 1510-1535

##### Urosepsis

Sondos Jarrad, United Arab Emirates

#### 1535-1545

##### Use of Chlorhexidine 0.1% for Urethral Cleaning in Pre- and Post- Foley's Catheter Insertion (Evidence-Based Practice)

Marcerey Sison Quejada, United Arab Emirates

#### 1545-1555

##### Structuring Skin Care to Prevent Incontinence Associated Dermatitis

Marilou Mendoza-Manarang, United Arab Emirates

#### 1555-1605

##### Comparative Study of Incontinence Associated Dermatitis Treatments- (Evidence-based practice)

Marilou Mendoza-Manarang, United Arab Emirates

## 1605-1610

### Q&A

Marilou Mendoza-Manarang, United Arab Emirates  
Marcerey Sison Quejada, United Arab Emirates

## 1610-1615

### Closing Remarks and Invitation to 7th SIU Global Nurses' Educational Symposium

Hussam Al Nusair, United Arab Emirates  
Amparo Gudrun Camacho, United States

### Learning Objectives

At the end of this session, attendees will be able to:

- Review diagnosis and surgical treatment for bladder cancer
- Discuss ostomy care interventions
- Discuss ERAS protocol basics
- Establish erectile dysfunction treatment compliance in men with prostate cancer and how this affects their recovery
- Determine infection control interventions for penile prosthesis
- Describe the causes and treatment of lower urinary tract dysfunction, including the newest therapies for prostate enlargement
- Consider voiding dysfunction interventions and the use of intermittent catheterization
- Evaluate the role of imaging and novel biomarkers in the treatment of patients with prostate cancer on active surveillance
- Describe nursing considerations when conducting prostate biopsies
- Detail urodynamic testing setup and its interpretation
- Review neuromodulation as treatment modality in voiding dysfunction
- Detail surgical approaches to urinary stone disease
- Describe operating room settings for stone surgery and laser safety
- Define treatment of urosepsis and the use of skin cleansers during Foley catheter insertions
- Discuss skincare considerations for patients with wounds and dermatitis

*This session is supported by SIU Corporate Sponsor Coloplast.*

## 0900-1030

### DEMO - Tips and Tricks in fURS

#### Chair

Wissam Kamal, Saudi Arabia

#### ROOM: Abu Dhabi B

#### Faculty

Mudhar Nazar Hassan, United Arab Emirates

*Pre-registration is required for this session.*

This session will focus more on endourological procedures (RIRS and PCNL) in terms of instrumentation, technique and tips and tricks.

### Learning Objectives

- Assess indications of each technique (PCNL and RIRS)
- Compare instrumentation for each technique (disposable vs. reusable equipment)
- Recognize the basics of endoscope manipulation and laser applications
- Understand the principles of management of endourological complications

*This session is supported by SIU Corporate Sponsor: Coloplast.*

## 0900-1200

### INN-02: Prostate MRI Reading and Fusion Biopsy Hands On Training Course

#### Co-Chairs

Christof Kastner, United Kingdom  
Tristan Barrett, United Kingdom

#### ROOM: Sheikh Rashid B

#### Faculty

Jurgen Fütterer, the Netherlands

*Pre-registration is required for this session.*

## 0900-0905

### Welcome and Introduction to Prostate Cancer Diagnostics and the Role of MRI

Christof Kastner

## 0905-1040

### MRI Workshop

Tristan Barrett

## 0905-0917

### Tutorial: Prostate MRI and PI-RADS

## 0917-0922

### DynaCAD Introduction

Presented by Philips

## 0922-0957

### Hands-On: MRI Case Analysis DynaCAD - Basic

## 0957-1005

### Tutorial: Pearls & Pitfalls of Reading and Reporting

## 1005-1040

### Hands-On: MRI Case Analysis DynaCAD - Basic-Item

## 1040-1055

### Integration of MRI and Fusion Biopsy into the Diagnostic Pathway

Christof Kastner

## 1055-1130

### Biopsy Workshop

Christof Kastner

1055–1105

## **Tutorial: Biopsies Using Prostate MRI**

1105–1130

## **Live & On-Screen Demo by Industry: Advanced Biopsy Equipment**

1130–1145

## **Value and Use of MRI Based Assessment in Treatment Decision and Surveillance of Prostate Cancer**

Jurgen Fütterer

1150–1200

## **Discussion and Finish**

### **Learning Objectives**

At the end of this session, attendees will be able to:

- Recall key features of systematic prostate MRI reading according to PI-RADS standards
- Read and report basic and intermediate level prostate MR imaging with confidence
- Recognize the technical features and capabilities of prostate biopsy and fusion technology using
- MR imaging for targeting
- Identify the key requirements to safely integrate MR imaging into the prostate diagnostic pathway

*This session is supported by SIU Congress Contributors: Koelis, MedCom and Philips.*

1245–1415

## **Luncheon Symposium: Immunotherapy in MIUC: Current Practices and Future Perspectives**

### **Chair**

James Catto, United Kingdom

**ROOM: Sheikh Maktoum BC**

### **On-Site Moderator**

Peter Black, Canada

### **Faculty**

Syed Hussain, United Kingdom

Srikala Sridhar, Canada

Fred Witjes, the Netherlands

### **Learning Objectives**

At the end of this session, attendees will be able to:

- Review the most recent guidelines for MIUC
- Examine current challenges and opportunities for improving patient outcomes
- Review the potential role of immunotherapy in MIUC management
- Analyze emerging data from key clinical trials of immunotherapies in MIUC, including monotherapy, dual therapy, and combination therapy

- Discuss patient stratification in the treatment decision-making for MIUC, with emphasis on the potential impact of immunotherapies in each patient setting

*This session is supported by SIU Corporate Sponsor: Bristol Myers Squibb.*

1245–1400

## **Luncheon Symposium: What Makes a Penile Implant Patient Happy? Best Practices for Improving Patient and Partner Satisfaction after PPI in 2021**

### **Chair**

Steven Wilson, United States

**ROOM: Sheikh Maktoum A**

### **Panelists**

Sébastien Beley, France

Rafael Carrion, United States

David Ralph, United Kingdom

Koenraad van Renterghem, Belgium

### **Learning Objectives**

At the end of this session, attendees will be able to:

- Review the common complications emerging from PPI surgery in the clinical practice and their impact on patient satisfaction.
- Analyze pre-, intra-, and postoperative strategies for improving outcomes and patient satisfaction following PPI.
- Discuss the current tools available for evaluating patient and partner satisfaction after PPI, including their limitations and opportunities for improvement.

*This session is supported by SIU Corporate Sponsor Coloplast.*

Sheikh Rashid Hall E



Aisles must remain free from obstruction and will be two directional, unless less than a 4m width.



Follow direction signage and  
adhere to maximum capacities in all areas

# EXHIBITORS

EXHIBITOR	BOOTH	EXHIBITOR	BOOTH
AKO MEDICAL/CONMED	442	NEOTRACT / TELEFLEX	100
ALGORITHM	110	PHARMAX	122
ANGIODYNAMICS	224	PHILIPS	120
ARAMED	512	PHOENIX MEDICINES	132
ASTELLAS UTECH CHARGING LOUNGE	230	PIERRE FABRE	200
BAYAN MEDICAL COMPANY	440	PUSEN	210
BAYER ONCOLOGY	530	QUANTA SYSTEM	400
BD	130	ROCAMED	300
BOSTON SCIENTIFIC	430	SAJA	334
COLOPLAST	410	SCIVITA MEDICAL	504
EDAP TMS	112	SOCIÉTÉ INTERNATIONALE D'UROLOGIE	220
ELIS PHARMACEUTICALS	510	SPIMACO	500
ELECTRO MEDICAL SYSTEMS (EMS)	330	STORZ MEDICAL AG	310
EMIRATES UROLOGY SOCIETY/ ARAB ASSOCIATION OF UROLOGY	202	TABUK	246
EVA PHARMA	124	uRCADÉ	220
GULF DRUG/OLYMPUS	212	VIATRIS	532
JANSSEN	104	WELLSPECT	522
KARL STORZ	310	WORLD BLADDER CANCER PATIENT COALITION	520
LILLY	524	ZAHRAWI GROUP	332
NAEL MEDICAL	502		

## PARTNER AND EXHIBITOR LISTING



### AKO MEDICAL/CONMED EXHIBITOR

BOOTH 442

In AKO Medical, we thrive on bringing the latest clinical solutions to the Middle East. We have partnered with ConMed, a 50-year-old US-based company that serves the surgical field through a wide-ranging product portfolio, leading the market of low-impact laparoscopy using their patented device, Airseal iFS. Airseal iFS gives surgeons a stable working space along with an excellent automated smoke evacuation ability by recirculating and filtering insufflated gas using dual-fine 0.01-µm ULPA filters. This protects both patients and operating room staff from smoke pathogens, while keeping the operating site clear. Combined, these two performance capabilities result in low-impact laparoscopy that reduces intra- and post-operative patient complications, allowing patients to recover earlier. World-renowned surgeons, such as Prof. Alex Mottrie, use the Airseal iFS exclusively.

▶ Ahmed Attia Maryem Thaeer  
[Ahmed.attia@ako-medical.com](mailto:Ahmed.attia@ako-medical.com) [Maryem.thaeer@ako-medical.com](mailto:Maryem.thaeer@ako-medical.com)  
+971543035308 +971544413873

Mohamed Salah  
[Mohamed.Salah@ako-medical.com](mailto:Mohamed.Salah@ako-medical.com)  
+971562590031

Islam Alaa  
[Islam.Alaa@ako-medical.com](mailto:Islam.Alaa@ako-medical.com)  
+971508119061



### ANGIODYNAMICS CONGRESS CONTRIBUTOR EXHIBITOR

BOOTH 224

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products. For more information, visit [www.angiodynamics.com](http://www.angiodynamics.com).

▶ [csinternational@angiodynamics.com](mailto:csinternational@angiodynamics.com)  
+31 20 7532939  
f angiodynamics t @angiodynamics in angiodynamics



### ALGORITHM SILVER SPONSOR EXHIBITOR

BOOTH 110

Algorithm is a regional pharmaceutical company committed to improving human health and well-being, operating in the Middle East and North Africa (MENA) region. We focus on innovative products either under license from international companies or differentiated generics in these therapeutic lines: cardio-metabolic, neurology, urology, pain and inflammation, and gastroenterology and infectiology.

We are proud to have built our culture and reputation around core values that guide us and shape our future: trust and respect, ethics and integrity, responsibility and accountability, and quality and excellence.

▶ [www.algorithm-lb.com](http://www.algorithm-lb.com)

Hosam Saad  
[Hsmahmoud@algorithm-lb.com](mailto:Hsmahmoud@algorithm-lb.com)  
Tel +971 503782865



### ARAMED BRONZE SPONSOR EXHIBITOR

BOOTH 512

With 18 years of success and expertise in the field of medical esthetic devices, products, dermal fillers, and cosmeceuticals.

ARAMED | Arabian Medical Enterprises LLC was founded by Eng. Khaled Haj Younes in 2003, establishing the first office in the United Arab Emirates. In 2005, we successfully crossed borders for the first time, expanding our venture to the GCC market. Today, we proudly cover the entire Middle East and North Africa region, and are celebrating 18 years of success and expertise with a remarkable presence in the industry and an outstanding position among our competitors.

ARAMED sets the highest standards in the field of medical esthetic devices, products, dermal fillers, and cosmeceuticals. ARAMED is driven by a unique team that consists of doctors, pharmacists, engineers, technicians, specialists, and support staff working together, utilizing a multitude of innovative approaches, after-sales service, and marketing support to provide complete customer satisfaction.

▶ [www.aramed.ae](http://www.aramed.ae)  
[www.elesta-echolaser.com](http://www.elesta-echolaser.com)

Ayman Alhati  
[ayman.alhati@aramed.ae](mailto:ayman.alhati@aramed.ae)  
+971 509453635  
Fabio Andreola  
[f.andreola@elesta-echolaser.com](mailto:f.andreola@elesta-echolaser.com)

Bruno Scotti  
[b.scotti@elesta-echolaser.com](mailto:b.scotti@elesta-echolaser.com)  
Manuela Consiglio  
[manuela.consiglio@gmail.com](mailto:manuela.consiglio@gmail.com)

## PARTNER AND EXHIBITOR LISTING



### ASTELLAS UTECH CHARGING LOUNGE CORPORATE SPONSOR EXHIBITOR

BOOTH 230

Astellas is a pharmaceutical company committed to turning innovative science into value for patients. Changing tomorrow is the ethos that guides everything we do. Across our areas of therapeutic expertise, we use our agility to match scientific breakthroughs to the unmet medical needs of people around the world, and the many healthcare professionals and caregivers who support them. Astellas invests in new medicines, technologies, and therapeutic areas, and builds partnerships and networks with others who share our vision to improve the future of medicine. Astellas is working at the forefront of healthcare change and the values of patient focus, ownership, results, openness, and integrity are the foundation of our culture.

► [www.astellas.com/en](http://www.astellas.com/en)



### BAYAN MEDICAL EXHIBITOR

BOOTH 440

Bayan Medical Company offers services and devices to healthcare professionals in partnership with BK Ultrasound, the world-class leading manufacturer of ultrasound devices. With award-winning systems and unique transducer designs, BK Ultrasound directly addresses the specialized needs and clinical challenges of urologists worldwide, offering unsurpassed imaging capabilities that enable real-time image guidance with easy-to-use mobile platforms. Bayan Medical Company offers solutions for procedures such as brachytherapy, MRI fusion biopsy, colorectal surgery, and HPB surgery.

Bayan Medical Company also enjoys successful partnerships with some of the leading medical device manufacturers, such as Medtronic, B. Braun, Cryolife, JOTEC, and others. With the capabilities of our dedicated trained sales and service staff, we provide the best customer service and effective solutions to our esteemed clients. We value integrity, customer focus, creativity, and operating excellence. As our accomplishments grow, so do our responsibilities; we support HCP community events and continuous medical education programs.

► [www.bayanmed.com](http://www.bayanmed.com)



### BAYER ONCOLOGY EXHIBITOR

BOOTH 530

NUBEQA®, given in a 300-mg darolutamide film-coated tablet, is used to treat adult men with prostate cancer that has not spread to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone. NUBEQA® blocks the activity of androgens, such as testosterone. By blocking these hormones, it stops prostate cancer cells from growing and dividing. The recommended dose is 2 tablets 2 times daily, although your doctor may reduce your dose to 1 tablet 2 times daily if you have problems with your liver or kidneys. Talk to your doctor or pharmacist before taking NUBEQA®, and do not stop taking this medicine unless your doctor tells you to. Please refer to the product package insert leaflet (PIL) for full product information and usage data.

View more information here: [https://www.siu-urology.org/themes/web/assets/files/congress/siu\\_2021/industry/nubeqa\\_-\\_pil\\_oct-2020\\_-\\_me.pdf](https://www.siu-urology.org/themes/web/assets/files/congress/siu_2021/industry/nubeqa_-_pil_oct-2020_-_me.pdf)

► [www.middleeast.bayer.com](http://www.middleeast.bayer.com)

Inas Reda  
Digital Product Manager Oncology  
[inas.reda@bayer.com](mailto:inas.reda@bayer.com)  
+971 56 896 2560



### BD EXHIBITOR

BOOTH 130

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics, and delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical and clinical laboratory research.

► Joseph Edward  
[Joseph.youssef@bd.com](mailto:Joseph.youssef@bd.com)  
+971 547932467

## PARTNER AND EXHIBITOR LISTING



Advancing science for life™

### BOSTON SCIENTIFIC EXHIBITOR

BOOTH 430

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. We are proud of our history of partnering with customers to advance urology. Our investments in this 25-year partnership have led to breakthrough innovations, and we continue to advance the science of urology together. As the healthcare landscape changes, your needs are growing. We are evolving from a medical device supplier into a urology solutions partner. Visit our exhibit to experience our latest innovations and solutions inspired by insights from patients, physicians, OR leaders and partners like you.

► [www.bostonscientific.com/urology](http://www.bostonscientific.com/urology)

Marisa Forsberg  
[marisa.forsberg@bsci.com](mailto:marisa.forsberg@bsci.com)  
+1 612 819 5674  
► [@bsc\\_urology](#) [in](#) bsc-uroph



### BRISTOL MYERS SQUIBB CORPORATE SPONSOR

VIRTUAL BOOTH

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at [BMS.com](http://BMS.com)

► [www.bms.com](http://www.bms.com)



### COLOPLAST CORPORATE SPONSOR EXHIBITOR

BOOTH 410

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions to include stress urinary incontinence, pelvic organ prolapse, kidney stones, and ED. Products include Titan® Touch, Restorelle®, Altis®, and ReTrace®.

*Coloplast is the recipient of the SIU 2021 Distinguished Partner Award.*

► [www.coloplast.us](http://www.coloplast.us)

Coloplast Corp.  
[usmedweb@coloplast.com](mailto:usmedweb@coloplast.com)  
1-800-258-3476  
1601 West River Rd  
Minneapolis MN 55411  
Customer Service



### EDAP TMS CONGRESS CONTRIBUTOR EXHIBITOR

BOOTH 112

EDAP TMS is a high-tech medical company listed on Nasdaq (EDAP) that develops, manufactures, and markets minimally invasive medical devices using ultrasound technology for various medical applications and offers a wide portfolio of complementary distribution products in urology.

Strongly investing in R&D activities and partnering with renowned medical research institutions since its inception in 1979, today EDAP TMS's development efforts are focused on making high intensity focused ultrasound (HIFU), a standard therapy for soft tissue ablation.

Based near Lyon, France, the company actively operates worldwide with subsidiaries and offices in the United States, Japan, Germany, Malaysia, South Korea, the United Arab Emirates, and Russia, as well as through more than 70 distribution partners.

The HIFU and ESWL divisions market products developed and manufactured by EDAP TMS for the treatment of prostate cancer and urinary stones. To complete EDAP's product offering, the distribution division also markets third-party devices in the urology space.

► [www.edap-tms.com](http://www.edap-tms.com)

Mathias Lehodey  
[mlehodey@edap-tms.com](mailto:mlehodey@edap-tms.com)  
+971 551 768 163

## PARTNER AND EXHIBITOR LISTING



### ELIS PHARMACEUTICALS EXHIBITOR

BOOTH 510

Elis Pharmaceuticals is engaged in developing, marketing, and commercializing proprietary medicines. We are commercializing our flagship product, Vitaros® (alprostadil), in the Middle East. Vitaros® uses a small drop of topical cream in a disposable applicator to treat erectile dysfunction. It has significant efficacy, including in difficult-to-treat populations:

- Patients who don't respond satisfactorily to PDE5 inhibitors'
- Diabetic patients
- Hypertensive and cardiac patients
- Patients on nitrates and alpha blockers
- Prostatectomy patients

Vitaros® is approved by the Medicines and Healthcare products Regulatory Agency and Health Canada, and is registered in almost 30 countries including the United Arab Emirates and Lebanon.

► [www.elispharma.com](http://www.elispharma.com)

[vitaros.me](http://vitaros.me)  
[info@elispharmaceuticals.com](mailto:info@elispharmaceuticals.com)  
+97145520807



### EMIRATES UROLOGY SOCIETY / ARAB ASSOCIATION OF UROLOGY CO-HOST EXHIBITOR

BOOTH 202

The Emirates Urological Society (EUS) strengthens and promotes the practice of urology medicine to improve the quality of life of the people of the United Arab Emirates; support the promotion of healthcare awareness; and foster the maintenance of high standards of care in urology by facilitating access to the latest innovations and quality scientific and medical education to meet the needs of its members.

► [www.eus.ae](http://www.eus.ae)

The Arab Association of Urology (AAU) is a non-profit organization established in 1996 with a mission to connect all Arab national societies to provide their members with a high standard of education, research, and clinical practice in the field of urology.

► [www.araburology.org](http://www.araburology.org)

Shruthi Rao  
[s.rao@araburology.org](mailto:s.rao@araburology.org)  
+971505521840  
+97143116357



### E.M.S ELECTRO MEDICAL SYSTEMS SA EXHIBITOR

BOOTH 330

EMS has shaped the history and future of stone management for 30 years, contributing to more than 13 million stone-free patients. Today, EMS is focused on providing stone management solutions for all stones, expanding our offering to cover both rigid and flexible endoscopic treatment.

► [www.ems-urology.com](http://www.ems-urology.com)

Charles McCurrach  
[cmccurrach@ems-ch.com](mailto:cmccurrach@ems-ch.com)  
+41 79 780 93 91  
@EMSurology in EMS-urology



### EVA PHARMA EXHIBITOR

BOOTH 124

EVA Pharma for pharmaceutical and medical industries was established in 1997. EVA Pharma is one of Egypt's leading pharmaceutical companies, built on the heritage of Les Laboratoires Delta, Egypt's second oldest pharmaceutical company. Today, EVA Pharma is the fastest growing pharmaceutical company in the MENA region, growing at a rate of more than 30% CAGR for the past seven years and transforming from a successful local company into a world-class multinational organization with sales and marketing presence across the region. EVA Pharma is present in more than 40 countries in Africa, Asia, Europe, North America, and Central America, where it has many products that are registered and sold.

Vision: Empower the fight for health and well-being as a human right.

Mission: A purpose-driven, diverse team that strives to save and improve millions of lives by sustainably offering accessible high-value medicines and healthcare solutions that address local patients' needs.

► [www.evapharma.com](http://www.evapharma.com)

Mina Mounir, Regional Product Manager  
[mina.mounir@evapharma.com](mailto:mina.mounir@evapharma.com)  
+201069995594

## PARTNER AND EXHIBITOR LISTING



### EXACT IMAGING CONGRESS CONTRIBUTOR

Exact Imaging ([www.exactimaging.com](http://www.exactimaging.com)) is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging with guided transrectal and transperineal biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use and, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system's 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application, has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

► [www.exactimaging.com](http://www.exactimaging.com)

Brian Wodlinger, PhD  
VP, Engineering and Clinical  
[bwodlinger@exactimaging.com](mailto:bwodlinger@exactimaging.com)  
+1 905 415 0030 x204



### JANSSEN BRONZE SPONSOR EXHIBITOR

BOOTH 104

About the Janssen Pharmaceutical Companies of Johnson & Johnson.

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

► [www.janssen.com](http://www.janssen.com)

Nour Safieddine, Pharm D  
Oncology Product Specialist  
[nsafiedd@its.jnj.com](mailto:nsafiedd@its.jnj.com)  
+971 562441875

► @JanssenGlobal



### GULF DRUG / OLYMPUS BRONZE SPONSOR EXHIBITOR

BOOTH 212

Gulf Drug has an accomplished reputation for the quality of medical equipment it provides, and its responsive nature has positioned it as a pioneer of the healthcare services sector across the Middle East Region. Olympus, being one of our partners in the United Arab Emirates, is committed to the ongoing pursuit of innovation, constantly aiming to further improve the level of patient care in urology and unrelentingly dedicated to the development of new innovative products and the high-quality training of urologists. To achieve these goals, Olympus cooperates intensively with leading experts in this field.

► [www.gulfdrug.com](http://www.gulfdrug.com) / [www.olympus-europa.com/medical](http://www.olympus-europa.com/medical)

Hamdan Al Masri  
[Hamdan\\_almasri@gulfdrug.com](mailto:Hamdan_almasri@gulfdrug.com)  
+971 556829040



### KARL STORZ CORPORATE SPONSOR EXHIBITOR

BOOTH 310

KARL STORZ, a family-owned company founded in Tuttlingen (Germany) in 1945, is a globally recognized market leader and solution provider in endoscopy for human and veterinary medicine. With its innovative endoscopes, instruments, units, services, and integrated solutions, KARL STORZ has stood for reliability, quality, and availability for over 75 years. Its portfolio of endoscopic instruments includes more than 15,000 products. In dialogue with medical professionals, KARL STORZ shapes and defines medical progress. Innovation, precision, and creativity are the hallmarks of KARL STORZ's work. The company combines stability with flexibility, anticipating the future while remaining grounded in tradition.

From its headquarters in Tuttlingen, KARL STORZ has grown from a two-person company into a global corporation that now employs 8,500 people at over 50 subsidiaries and is represented in more than 40 countries.

► [www.karlstorz.com](http://www.karlstorz.com)

[info@karlstorz.com](mailto:info@karlstorz.com)  
KARL STORZ SE & Co. KG  
Dr.-Karl-Storz-Strasse 34  
78532 Tuttlingen  
Germany  
+49 (0) 7461 708 0

# PARTNER AND EXHIBITOR LISTING



**KOELIS**  
CONGRESS CONTRIBUTOR

VIRTUAL EXHIBITOR

KOELIS has assisted physicians from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer management. Based in Grenoble with subsidiaries in Princeton and Hong Kong, KOELIS has been featured in more than 80 clinical publications and has benefited more than 300,000 patients on all continents. Focused on developing targeted and less invasive solutions, KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians the newest advances in imaging for delivering efficient and patient-tailored solutions. For more information, please visit our website, [www.koelis.com](http://www.koelis.com), or our YouTube channel, [www.youtube.com/user/KoelisBx](https://www.youtube.com/user/KoelisBx).

► [www.koelis.com](http://www.koelis.com)

Paul Pommel  
[pommel@koelis.com](mailto:pommel@koelis.com)  
+33 6 80 63 45



**MEDCOM**  
CONGRESS CONTRIBUTOR

MedCom is a Darmstadt (Germany)-based company and specializes in the field of medical imaging. For more than 20 years, MedCom has been offering innovative and advanced imaging-based products with emphasis on interventional/surgical navigation and cancer treatment solutions. MedCom developed the first commercially released "fusion imaging" with integrated intervention planning product for liver (2002) and prostate (2007). MedCom's fusion system BiopSee® was CE cleared in 2011 and FDA approved in 2017 with numerous installations worldwide. As an OEM/B2B company, MedCom provides a range of products for various global corporations with integrated clinical solutions and is also working on projects in cooperation with high-end clinics in the research sector.

► [www.medcom-online.de](http://www.medcom-online.de)  
[www.biopsee.de](http://www.biopsee.de)

Ilias Skalkidis  
[iskalkidis@medcom-online.de](mailto:iskalkidis@medcom-online.de)  
+49 6151 95147 286



**LILLY**  
BRONZE SPONSOR  
EXHIBITOR

BOOTH 524

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

► [www.lilly.com](http://www.lilly.com)



**MERCK**  
CORPORATE SPONSOR

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs, and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.

► [www.merck.com](http://www.merck.com)

► @Merck f MerckInvents @merck Merck in Merck



*I am a urologist.  
I am a patient.*

**“** When my BPH symptoms became unbearable I really didn't want to undergo invasive surgery and I'm not a personal fan of BPH medications. Relief can be inadequate and temporary and they have a whole host of side effects. **”**

**Peter J. Walter, M.D., F.A.C.S.\*** Western New York Urology Associates and UROLIFT® SYSTEM PATIENT

Enlarged Prostate (BPH) affects over 40 million men in the United States. Symptoms may include interrupted sleep and urinary problems as well as loss of productivity, depression and decreased quality of life.<sup>2</sup>

If your patients have symptoms of an enlarged prostate, introduce them to the UroLift® System. Here's why I chose UroLift System and recommend it to my patients.

**Proven**, minimally invasive approach to treating enlarged prostate that provides rapid symptom relief and recovery<sup>3,4</sup>




**An earlier alternative** to medical therapy that provides symptom relief better than reported for medication<sup>3,5</sup>

**Durability** through 5 years<sup>6</sup>

**Over 175,000\*\*** men have been treated with the UroLift System worldwide

The procedure is **covered by Medicare** and all major private insurers when medical criteria are met.

Learn more and check out the data at [UroLift.com/info](http://UroLift.com/info)



The UroLift System procedure is FDA-cleared for the treatment of symptoms due to urinary outflow obstruction secondary to BPH, including lateral and median lobe hyperplasia, in men 45 years of age or older. Results and patient experience may vary. Clinical data from a pivotal 206-patient randomized controlled study showed that most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within 2 to 4 weeks after the procedure.

\*Dr. Walter is UroLift System faculty and a paid consultant for NeoTract|Teleflex

\*\*Management estimate based on product sales and average units per procedure.

1. AUA Guidelines 2003, 2010; 2. Speakman et al. 2014 BJUI International; 3. Roehrborn J Urol 2013 L.I.F.T. Study; 4. Shore, Can J Urol 2014 Local Study; 5. AUA BPH Guidelines 2003; 6. Roehrborn et al. Can J Urol 2017

# PARTNER AND EXHIBITOR LISTING



## NAEL MEDICAL EXHIBITOR

BOOTH 502

Established in 1998, Nayel Medical Equipment Est is a trusted healthcare solutions provider and medical equipment distributor in United Arab Emirates and is a part of Nael and Bin Harmal Investment Company.

Nayel Medical Equipment Est specializes in dealing in medical furniture and urology, gynaecology, ENT, general surgery, and dermatology equipment, instruments, and consumables from well-known manufacturers around the world.

Under the urology division, we deal with stone management with the help of Quanta Laser Systems/Italy, EDAP TMS/France, and Seeshen/China.

The Quanta Laser System uses both holmium and thulium technologies to break kidney stones.

KOELIS Trinity used for MRI/ultrasound prostate fusion biopsy.

For urodynamics study, we use Hermes & SmartDyn from Albyn Medical.

Uroflowmetry measures with Smart Scales.

► Sujesh P.V.  
+971 0551004327

[www.naelmedical.com](http://www.naelmedical.com)



## PHARMAX PHARMACEUTICALS EXHIBITOR

BOOTH 122

Headquartered in Dubai, United Arab Emirates, Pharmax Pharmaceuticals, a group company of ADQ, is a GMP-licensed international manufacturer and distributor of high-quality medications in the MENA region.

Pharmax Pharmaceuticals is committed to maintaining a culture of quality at its state-of-the-art facility, which meets national and international regulatory standards. Committed to exceeding the expectations of healthcare providers, practitioners, and patients, Pharmax offers a diverse range of medications across a wide range of therapeutic areas, providing access to affordable, branded generic medications.

In March 2019, Pharmax was granted EU GMP approval, which opens up broader markets, including the European Union.

We are building our core competencies in:

- Product manufacturing
- Nurturing partnerships
- Sales and marketing

For us, it is all about partnership... We strive for strong, long-term partnerships with suppliers, distributors, and customers through:

- Providing contract manufacturing services
- Offering products through out-licensing and in-licensing
- Offering products through distribution deals

► [www.pharmax.ae](http://www.pharmax.ae)

Roula Siddik  
[roula.siddik@pharmax.ae](mailto:roula.siddik@pharmax.ae)  
+971 545039939



INTERVENTIONAL UROLOGY

## NEOTRACT TELEFLEX CONGRESS CONTRIBUTOR EXHIBITOR

BOOTH 100

The UroLift System procedure is a minimally invasive approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. There is no cutting, heating, or removal of prostate tissue. It is an earlier treatment alternative for more BPH patients. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 250,000 men have been treated with the UroLift System in select markets worldwide.

► [www.urolift.com/physicians](http://www.urolift.com/physicians)

Emma Dugan  
[emma.dugan@teleflex.com](mailto:emma.dugan@teleflex.com)  
+44 (0) 7788 721743

Mark Surgenor  
[mark.surgenor@teleflex.com](mailto:mark.surgenor@teleflex.com)  
+44 7423 452069

Rosalind Baynton  
[rosalind.baynton@teleflex.com](mailto:rosalind.baynton@teleflex.com)  
+44 7468 360388

Joost Kanen  
[joost.kanen@teleflex.com](mailto:joost.kanen@teleflex.com)  
+31643495990

Mohammed Abdullah  
[mohammedabdullah@naghi-medical.com](mailto:mohammedabdullah@naghi-medical.com)  
+971504090608

Daoud Udwan  
[daoududwan@naghimedical.com](mailto:daoududwan@naghimedical.com)  
+971553115226

# PHILIPS

## PHILIPS CONGRESS CONTRIBUTOR EXHIBITOR

BOOTH 120

Philips advanced prostate imaging and biopsy

Connect radiology and urology like never before with a complete, integrated clinical solution from Philips. From diagnosis and staging to treatment decision and follow-up, Philips is addressing challenges in prostate cancer care by providing solutions across the entire care delivery pathway.

Advances in multiparametric magnetic resonance imaging of the prostate now enhance the ability to visualize and evaluate clinically significant prostate lesions. Philips extends the power of MRI beyond radiology, with a comprehensive prostate care solution to help add clinical efficiency and enhanced collaboration across the care pathway. Utilize the Philips suite of prostate oncology tools for advanced visualization, urological review and planning, and MR/ultrasound fusion biopsy and ablation capabilities.

Our key solutions include: the UroNav MR/US-guided fusion biopsy system, DynaCAD Prostate post-process imaging software, and DynaCAD Urology for treatment planning and follow-up.

Meet with our expert team at the SIU to discover more.

► [www.philips.ae/healthcare/content-catalog/oncology/disease-management-solutions/prostate-solutions](http://www.philips.ae/healthcare/content-catalog/oncology/disease-management-solutions/prostate-solutions)

Vinay Oommen Thomas  
[vinay.thomas@philips.com](mailto:vinay.thomas@philips.com)  
+971 (55) 1523510

## PARTNER AND EXHIBITOR LISTING



### PHOENIX MEDICINES EXHIBITOR

BOOTH 132

Phoenix Medicines L.L.C was established in 2004 as an MOH-certified distributor in the United Arab Emirates. Our core business in the healthcare industry is to provide available products and services.

PHARMACEUTICAL  
UROCIT-K  
POTASSIUM CITRATE  
WAX MATRIX TABLETS  
10 meq  
Urocit-K  
Sodium/Sugar Free  
Sustained Alkalinizer  
FDA-approved product  
ZFLOX  
Moxifloxacin 400 mg

HYPER PHOTONIC  
35W HOLMIUM LASER  
STORZ MEDICAL  
ESWL LITHOTRIPSY RENTAL

MEDICAL SURGERY  
Endoscope Staplers  
Resection, transection, and  
anastomosis  
Ultrasound Scalpel  
General Surgeries and  
Pediatrics Surgeries  
Electrosurgical Instruments  
Tissue Sealer/Divider

MEDICAL DIVISION  
Marflow  
Disposable Urology Products  
OTU Medical  
Disposable Digital  
Ureteroscope

► [www.phoenixmedicines.ae](http://www.phoenixmedicines.ae)

Ovais Ahed & Sundar  
[ovais@phoenixmedicines.ae](mailto:ovais@phoenixmedicines.ae)  
+971 4 2275242



### PROCEPT BIROBOTICS CONGRESS CONTRIBUTOR

PROCEPT BioRobotics is a surgical robotics company developing transformative solutions in urology. The AquaBeam® Robotic System, delivering Aquablation® therapy, is the first FDA-cleared surgical robot providing autonomous removal of prostate tissue for the treatment of BPH.



Pierre Fabre

### PIERRE FABRE SILVER SPONSOR EXHIBITOR

BOOTH 200

Permixon, or Serenoa repens, is a well-established herbal product used as a medicinal product in the European Union for treatment of symptomatic benign prostatic hyperplasia (BPH). There are numerous branded Serenoa repens products, and they differ qualitatively and quantitatively because of differences in the source of the biological product and in the processes used to extract the active ingredients.

The European Medicines Agency (EMA) recently concluded that available evidence supported its use as a well-established medicinal product with recognized efficacy and acceptable safety. Permixon has also been marketed worldwide for more than three decades to treat lower urinary tract symptoms (LUTS) caused by BPH.

For the first time in 2021, the European Association of Urology (EAU) guidelines added clear recommendations for Permixon. It is now recommended for LUTS and a real place has been made for Serenoa repens in the Phytotherapy subsection of the guidelines.

► [www.pierre-fabre.com](http://www.pierre-fabre.com)

RAMEZ RAOUF  
Brand Manager  
Pierre Fabre Group - U.A.E.  
+971529306126  
[ramez.raouf@pfms-me.com](mailto:ramez.raouf@pfms-me.com)



### PUSEN SILVER SPONSOR EXHIBITOR

BOOTH 210

Zhuhai Pusen Medical Technology Co., Ltd., an innovative medical technology enterprise integrating research and development, production, and marketing, focuses on providing innovative and high-quality medical products for clinical practice. In development, we adhere to the concept of "base on the clinic and serve the clinic," continuing to innovate to bring safer medical products to clinic.

With excellent manoeuvrability and superior image quality, PUSEN's 9.2Fr Flexible Ureteroscope is a supported tool for treatment of urolithiasis, and has served many urologists from all over the world.

PUSEN's new product, the 7.5Fr Flexible Ureteroscope, is the latest technique of disposable flexible ureteroscope in the world, with its outer diameter of 7.5Fr, working channel of 3.6Fr, highly increase the stone-free rate for the urologists during the ureteroscopy, making it the preferred choice of many experts worldwide.

PUSEN will continuously specialize in the field of urology, R&D more innovative products in the future. Meanwhile, we would appreciate receiving any comment or suggestions about our products, which will guide us toward success.

► [www.pusenmedical.com](http://www.pusenmedical.com)

Celia Tang  
[celia.tang@pusenmedical.com](mailto:celia.tang@pusenmedical.com)  
86 (0) 756 6880401

## PARTNER AND EXHIBITOR LISTING



### QUANTA SYSTEM EXHIBITOR

BOOTH 400

Quanta System was created in 1985 as a spin-off of one of the largest research centres in the field of lasers and optics worldwide. In 2004, Quanta became part of the El.En. Group, listed on the Italian Stock Exchange. The group is one of the worldwide leading players manufacturing laser technology. The company has devoted energy and competencies to improve patients' lives by developing innovative lasers that meet real medical needs.

► [quanta@quantasystem.com](mailto:quanta@quantasystem.com)

Quanta System SpA  
Via Acquedotto 109  
21017 Samarate VA Italy  
+390331376797



ROCAMED

### ROCAMED EXHIBITOR

BOOTH 300

ROCAMED is a medical device company focused on human health, providing innovative solutions in urology, gynecology, and laparoscopy.

#### PATIENT FOCUSED

Understanding of patient needs

#### PREMIUM QUALITY

R&D investments

#### INNOVATION

Close collaboration with physicians

#### MANUFACTURER

#### EDUCATION

Training programs worldwide

Training programs worldwide

#### NETWORK

65+ countries

► [www.rocamed.com](http://www.rocamed.com)

Entela LILAJ  
Marketing Coordinator  
[le@rocamed.com](mailto:le@rocamed.com)  
+33(0)614053097



### SAJA GOLD SPONSOR EXHIBITOR

BOOTH 334

SAJA is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese pharmaceutical companies, Daiichi Sankyo Company Ltd and Astellas Pharma Inc.

SAJA was established in 1996 and introduced its first product to Saudi market in 2000. Since then, SAJA has expanded geographically and diversified its unique portfolio. SAJA has a rich portfolio of different therapeutic classes, and our urology franchise include the following items:

Omnice Ocas® (Tamsulosin ocas)  
Vesicare® (Solifenacin Succinate)  
Betmiga® (Mirabegron)  
Depojoy® (Dapoxetine)

► [www.sajapharma.com](http://www.sajapharma.com)

Mohamed Ghoniem  
Product Manager Gulf/Yemen  
[mohamed.ghoniem@sajapharma.com](mailto:mohamed.ghoniem@sajapharma.com)  
m: +971 971551977675  
p: +971 65554468  
f: +971 65592286  
C/o. City pharmacy  
P.O. Box: 23181, Sharjah  
United Arab Emirates



### SCIVITA EXHIBITOR

BOOTH 504

Scivita Medical is committed to the R&D, production, and sales of world-leading medical optical equipment and instruments.

The company operates R&D centres in Suzhou, China, and Tokyo, Japan, with teams of professionals in the fields of optics, machinery, automation, materials, mold design, and electronic information engineering. The product matrix covers both flexible and rigid endoscopes, including UHD technology, 3D visualization technology, special light imaging technology (e.g. fluorescence imaging), ultra-fine endoscopic technology, single-use technology, etc.

The company's manufacturing workshop is capable of manufacturing, assembling, testing, and aging of products. The 100k-level purification workshop is able to meet the production requirement of single-use electronic endoscopes. Scivita Medical brings new single-use urology videoscope with a larger angulation range of up to 285 degree and better image quality, and a uniform outer shaft diameter with excellent maneuverability. The special shaft rotation function helps to deal more accurately with the stone in the lower calyx.

► [www.scivitamedical.com](http://www.scivitamedical.com)

Sammi Liao  
[liaoshan@scivitamedical.com](mailto:liaoshan@scivitamedical.com)  
+8613661533316

## PARTNER AND EXHIBITOR LISTING



### SOCIÉTÉ INTERNATIONALE D'UROLOGIE HOST

BOOTH 220

Founded in 1907, the Société Internationale d'Urologie is a dynamic and inclusive society, serving 10,000 members from over 130 countries. Through partnerships with national urological societies around the globe, SIU is able to respond to the diverse needs of its members and offer relevant and innovative educational, networking and research opportunities.

Members benefit from

- Full free access to the SIU Academy e-learning platform
- Full access to SIU's Research platform, uCARE
- Significant discounts on SIU Congress registration
- An extensive network of global contacts in the urological community

SIU has its own academic journal, SIUJ, which publishes 6x/year. Visit our booth to find out more about SIU activities, including our upcoming congress in Montreal, Canada, November 9-13, 2022 and the B2B Uro-Oncology GU Cancers Triad Meeting, November 10, 2022.

► [www.siu-urology.org](http://www.siu-urology.org)

[central.office@siu-urology.org](mailto:central.office@siu-urology.org)

+1 514 875 5665

f SIUurologyIntl @SIU\_urology in siu-urology-org



### SPIMACO EXHIBITOR

BOOTH 500

SPIMACO is a Saudi joint stock company. SPIMACO is the only Saudi pharmaceutical company listed and quoted in the Saudi stock market. It was established in 1986, with the main objective of setting up an advanced pharmaceutical industry in the Kingdom of Saudi Arabia.

SPIMACO has developed a strong position in Saudi Arabia—it is ranked in the 1st position in the Saudi pharma private market and its revenues in the year 2020 were reached up to SAR 1.8 billion (USD 0.5 billion).

Furthermore, SPIMACO is a leading regional pharmaceutical company that operates in 14 countries in the MENA region and has plenty of strategic alliances with almost all big multinational pharmaceutical companies.

SPIMACO owns a unique portfolio directed to urologists in antibiotics ((Ciprofloxacin [Cipromax]/[Levofloxacin][Velox]/[Moxifloxacin][Moxive]) ([Snafi, Tadalafil 20 mg. 5 mg.], Wafi [Sildenafil], Lejam [Dapoxetine]).

► [www.spimaco.sa](http://www.spimaco.sa)

Alaa Ahmed

[Alaa.ahmed@spimaco.sa](mailto:Alaa.ahmed@spimaco.sa)

+971 0505788655



### STORZ MEDICAL AG

BOOTH 310

#### CORPORATE SPONSOR EXHIBITOR

Established in 1987, STORZ MEDICAL AG is an independent partner company of the KARL STORZ Group. STORZ MEDICAL offers a wide range of innovative and internationally renowned extracorporeal lithotripters for any clinical demand, from a compact modular system such as our MODULITH SLK »Intelect« up to a high-end integrated system like the MODULITH SLX-F2 »connect«, which can serve as a urological workstation with built-in shock wave system for endourological procedures and SWL. Today, the focus is on personalized stone management, making it possible to tailor each patient's treatment to their own particular situation.

Our DUOLITH SD1 T-TOP »ultra« can also be used in the targeted treatment of pathologies and opens up a new area of application, namely vascular erectile dysfunction. The focused shock wave therapy (Li-ESWT) can be effectively used in urological pain therapy, such as CPPS and Peyronie's disease.

► [www.storzmedical.com](http://www.storzmedical.com)

+41 71 677 45 45

@storz\_medical in STORZ MEDICAL AG @storz\_medical



### TABUK EXHIBITOR

BOOTH 246

Tabuk Pharmaceuticals Manufacturing Company (part of ASTRA Industrial Group [AIG] which is one of the leading industrial conglomerates in the Kingdom of Saudi Arabia) develops, manufactures, markets, and distributes a wide range of branded generic pharmaceuticals and under-licensed products globally. Tabuk aims to positively impact people's quality of life by developing high-quality drugs. Tabuk is ranked as the largest privately owned pharmaceutical company in KSA with leading position in both private and public sector in MENA region. Tabuk Pharmaceuticals has one of the richest pharmaceuticals portfolios in the MENA region, covering a wide range of therapeutic areas including urogenital products. We distribute pharmaceutical products in seventeen countries worldwide, and represent several international companies in the field of pharmaceuticals, cosmetics, medical devices, and food supplements through our dedicated agency and distribution arm. We have strong manufacturing capabilities and four state-of-the-art manufacturing sites in Saudi Arabia, Sudan, and Algeria, and our experienced research and development team adopts the latest technologies as they add new products to our portfolio.

Please visit us at stand 246.

► [www.tabukpharmaceuticals.com](http://www.tabukpharmaceuticals.com)

Reda Ezz El Din

Group Product Manager

Tabuk Representative Office,

P.O. Box 505218, Dubai

United Arab Emirates

+971 4 4243031 Mob: +971 50 97 940 13

# PARTNER AND EXHIBITOR LISTING



## URCADE HOST

BOOTH 220

uRCADe is the SIU's Official Educational Gaming arcade. This platform hosts gamified educational activities that are designed for urologists, medical oncologists, radiation oncologists, residents, and fellows who have an interest in immunotherapy and systemic treatments for bladder cancer (I-O+ Challenger) and renal cell carcinoma (RCC Quest).

In addition, these activities allow us to evaluate the gaps in knowledge of participants and design relevant medical education programmes.

Play during SIU 2021 and enter for a chance to win complimentary registration to the 2022 B2B Uro-Oncology GU Cancers Triad Meeting, in Montreal, Canada and to win points for the SIU 2021 Scavenger Hunt game on the SIU Mobile app.

These games are made possible by unrestricted educational grants from F. Hoffmann-La Roche Ltd., and Merck & Co., Inc.

The I-O+ Challenger is endorsed by the World Bladder Cancer Patient Coalition.

► [www.siu-urology.org/urcade/urcade](http://www.siu-urology.org/urcade/urcade)

[central.office@siu-urology.org](mailto:central.office@siu-urology.org)

+1 514 875 5665

f SIUurologyIntl @SIU\_urology in siu-urology-org



## VIATRIS EXHIBITOR

BOOTH 532

In a world that is perpetually changing, there is an increasing need for companies demonstrating the courage to face emerging healthcare challenges. Viatris is a new global healthcare company formed through the combination of Mylan and Upjohn, a legacy division of Pfizer.

► [www.viatris.com](http://www.viatris.com)

George Sadek

[George.sadek@viatris.com](mailto:George.sadek@viatris.com)

+971 506583457



## WELLSPECT EXHIBITOR

BOOTH 522

We passionately strive to make a real difference every day to everyone who is suffering from urinary retention or chronic constipation. These include people who have a spinal cord injury, multiple sclerosis, an enlarged prostate, spina bifida, or other conditions. We focus on improving their independence with discrete and easy-to-use continence management products and services.

Our primary concern is always for the well-being of our users. Their conditions affect their lives at work, at home, and when they are with family and friends. Wellspect products and services help them to overcome challenges that would otherwise restrict their lives. We give our users more time for life.

► [www.wellspect.com](http://www.wellspect.com)

Mohannad Mustafa

[mustafa.mohannad@wellspect.com](mailto:mustafa.mohannad@wellspect.com)

+971 52 6906322



## WORLD BLADDER CANCER PATIENT COALITION EXHIBITOR

BOOTH 520

The World Bladder Cancer Patient Coalition (WBCPC) strives to ensure national bladder cancer patient organizations are strong enough to support people affected by bladder cancer, enhance awareness, and advocate for better diagnosis, access, and care.

Established in 2019, the World Bladder Cancer Patient Coalition (WBCPC) is the first-time people affected by bladder cancer have a force connecting bladder cancer patients, groups, and organisations working to ensure the best possible outcomes for bladder cancer patients around the world.

Our mission focuses on three goals:

- To foster an international community of people affected by bladder cancer
- To advocate for access to the best bladder cancer information, support, and care
- To build alliances with health professionals, policymakers, academics, researchers, and industry

We are driven by our ambition to have a bladder cancer patient organization established in each country and that they are fully able to support people affected by bladder cancer, advocate for advancing research, and provide the best information, treatment, and care. The WBCPC is here to help grow, connect, and support these groups on their journey.

► [www.worldbladdercancer.org](http://www.worldbladdercancer.org)

Alex Filicevas

+32498712426

[alex.filicevas@worldbladdercancer.org](mailto:alex.filicevas@worldbladdercancer.org)

## PARTNER AND EXHIBITOR LISTING

---



---

### ZAHRAWI GROUP EXHIBITOR

BOOTH 332

Established in 1989, Zahrawi Group is one of the leading and pioneer Healthcare Solutions and Analytical Lab providers in the U.A.E. specialized in Surgical, Medical, Nuclear Medicine, Diagnostic and Analytical Lab. Started in Dubai, U.A.E, Zahrawi Group has an emphatic presence across the GCC with its own operations in the U.A.E, Saudi Arabia, Qatar, Bahrain and Oman. Throughout the years, Zahrawi Group has made its mission to introduce an extensive range of high-quality and advanced technology products to the Middle East market, enabling doctors and patients to access the best in terms of Healthcare. Our portfolio includes more than 200 internationals world-renowned manufacturers including but not limited to Laborie, Boston Scientific, Ems, Rocamed, Mediprema, Toray, Innovex Anqing Medical, Guerbert, Hitachi, Gymna, Hocoma, Kinetec.

► [www.zahrawigroup.com](http://www.zahrawigroup.com)

Fatima-zohra Jabri  
[fatima.jabri@zahrawigroup.com](mailto:fatima.jabri@zahrawigroup.com)  
+971 56 962 1010

Anas R. Tawil  
[anas.tawil@zahrawigroup.com](mailto:anas.tawil@zahrawigroup.com)  
+971 54 581 1159



**SAJA** is a joint venture between the premier Saudi healthcare company Tamer industries and two of the leading Japanese Pharmaceutical companies, Daichi Sankyo and Astellas Pharma.

Together with the Japanese partners, SAJA has invested in the most advanced pharmaceutical production facility yet seen in the Middle East, designed and built to the highest specifications, in strict accordance with Japanese standards.

SAJA was established in 1996 and introduced the first product to the Saudi market in 2000. Since then, SAJA has expanded geographically and has diversified its unique portfolio to provide innovative, high-quality medications in a variety of therapeutic areas.

**Contact details:**  
C/o. City pharmacy  
P.O. Box: 23181, Sharjah-UAE.  
Phone: +97165554468  
Fax: +97165592286

[www.sajapharma.com](http://www.sajapharma.com)

## SPONSOR ACKNOWLEDGEMENTS

---

The Société Internationale d'Urologie would like to extend its gratitude to its Corporate Sponsors, Society and Congress Contributors

### Corporate Sponsors



### Society Contributors



### Congress Contributors



## SPONSOR ACKNOWLEDGEMENTS

---

**The Société Internationale d'Urologie would like to extend its gratitude to its Gold, Silver, Bronze Sponsors and Partners**

---

### Gold Sponsor

---



---

### Silver Sponsors


---



---

### Bronze Sponsors

---



---

Destination Partner



Supported by



**SYMP-21 • Friday, November 12, 2021**  
1245-1315 Gulf Standard Time (UTC+4) Room: Sheikh Maktoum BC



## FOCAL HIFU THERAPY IN PROSTATE CANCER: PRACTICE CHANGES ON THE HORIZON?

### CHAIR




**Rafael Sanchez-Salas**  
MD  
Canada

### MODERATOR



**Franck Bladou**  
MD  
France

### PANELISTS



**Pascal Rischmann**  
MD, PhD  
France



**Martin Schostak**  
MD, PhD  
Germany

This session will be transmitted live via the SIU Congress platform, SIU @U

This session is supported by SIU Congress Contributor EDAP TMS.



#SIU2021 #SIUatU



# Actively Recruiting Clinical Trials

with BMS Immuno-Oncology Agents in Genitourinary Indications



	Study Name/Phase	Patient Population	Study Design	Primary Endpoints
Urothelial Carcinoma	CA017-078 <sup>1,2</sup> NCT03661320 Phase III	Patients with muscle-invasive bladder cancer eligible for radical cystectomy (RC)	Gemcitabine-cisplatin → RC → None (observation)	• Pathological Complete Response  • Event-free Survival
			BMS-986205 placebo + Nivolumab + Gemcitabine-cisplatin → RC → Nivolumab + BMS-986205 placebo	
			BMS-986205 + Nivolumab + Gemcitabine-cisplatin → RC → Nivolumab + BMS-986205	
	CA045-009 <sup>1,2</sup> NCT04209114 Phase III	Patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy	Nivolumab + Bempegaldesleukin → RC → Nivolumab + Bempegaldesleukin	• Pathological Complete Response  • Event-free Survival
			Nivolumab → RC → Nivolumab	
			None (standard of care) → RC → None (standard of care)	
	CA209-901 <sup>1,2</sup> NCT03036098 Phase III	Patients with previously untreated, unresectable, or metastatic urothelial cancer	Nivolumab + Gemcitabine + Cisplatin, then Nivolumab	• Overall Survival  • Progression-free Survival
			Gemcitabine + Cisplatin	
			(Study Design shown for arms C and D only)	

Study Name/Phase	Patient Population	Study Design	Primary Endpoints
Renal Cell Carcinoma	Patients with localized renal cell carcinoma who underwent partial or radical nephrectomy	Nivolumab + Ipilimumab	<ul style="list-style-type: none"> <li>Disease-free Survival</li> </ul>
		Placebo	
		Nivolumab	
CA209-914 <sup>1,2</sup> NCT03138512 Phase III	Patients with previously untreated kidney cancer that is advanced or has spread	Nivolumab + Bempegaldesleukin + Axitinib	<ul style="list-style-type: none"> <li>Incidence of Adverse Events</li> <li>Overall Response Rate</li> </ul>
		Nivolumab + Bempegaldesleukin + Cabozantinib	
		Nivolumab + Bempegaldesleukin + Cabozantinib	
CA045-011 <sup>1,2</sup> NCT04540705 Phase I/II		Nivolumab + Cabozantinib	

Study Name/Phase	Patient Population	Study Design	Primary Endpoints
Prostate Cancer	Men with metastatic castration-resistant prostate cancer who are chemotherapy-naïve	Docetaxel + Prednisone + Nivolumab	<ul style="list-style-type: none"> <li>Radiographic Progression-free Survival</li> <li>Overall Survival</li> </ul>
		Docetaxel + Prednisone + Placebo	
CA209-7DX <sup>1,2</sup> NCT04100018 Phase III			

Scan this QR Code to learn more at [BMSStudyConnect.com/GUcancers](https://www.BMSStudyConnect.com/GUcancers)



BMS=Bristol Myers Squibb; BCG=bacillus Calmette-Guerin; CIS=carcinoma in situ; PD-L1=programmed death-ligand 1; RC= radical cystectomy.

1. <https://www.clinicaltrials.gov/>. 2. <https://www.BMSStudyConnect.com> (Data accessed on September 23, 2021).



# Every single day is about ***Changing tomorrow.***

Each day we commit ourselves to answer the unmet needs of patients, building on our heritage in oncology, urology and transplant.

We follow the science and apply breakthrough research to further therapy areas including neuroscience, ophthalmology, nephrology, women's health, immunology and muscle diseases.

We are relentless in our mission to transform innovative science into value for our patients.

Find out more about us at:  
**[astellas.com/eu](https://astellas.com/eu)**

 **astellas**  
Changing tomorrow